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Abstract 
Electron transport and respiration in Mycobacterium tuberculosis (Mtb), the causative 
agent of tuberculosis (TB) occurs through the use of the aa3 type cytochrome c oxidase 
(CcO) under normoxic conditions or cytochrome bd oxidase (CbdO) under 
microaerophillia. Using these oxidases, Mtb couples substrate level oxidation to 
generation of metabolic energy in the form of adenosine triphosphate (ATP) under 
aerobic conditions. The presence of the CbdO is expected to allow for growth and 
survival of Mtb in the oxygen restricted environment of the human TB granuloma, thus 
rendering it an important enzyme for further study. CbdO is comprised of two structural 
subunits, CydA (subunit I) and CydB (subunit II), which are encoded by the cydAB 
operon. Both subunits span the cytoplasmic membrane to form part of the 
mycobacterial electron transport chain. Notably, two other genes that are transcribed 
separately from the cydAB operon, the cydDC operon, have been proposed to be 
required for the synthesis of a functional CbdO. Based on amino acid sequence and 
structural predictions, the cydDC encode heterodimeric members of the ATP Binding 
Cassette ABC-type transporters. In other organisms, the cydDC functions to transport 
reducing agents to the periplasm, thus contributing to periplasmic redox homeostasis. In 
this study we aimed to analyze the function of the cydDC genes in Mycobacterium 
smegmatis. Through bioinformatics analyses, it was demonstrated that the CydDC 
subunits retain conserved residues associated with the ABC domain and adopt a three-
dimensional fold that is similar to their counterparts in Escherichia coli. However, the 
published sequence of M. smegmatis suggests that cydC is a pseudogene, which was 
inconsistent with the demonstrated evidence of a functional CbdO in this organism. In 
this study, using standard DNA sequencing, it was demonstrated that the CBTBR 
laboratory strain of M. smegmatis does not harbor a cydC pseudogene but rather has a 
functional cydC gene. Next, we interrogated the function of the M. smegmatis and Mtb 
cydDC genes by heterologous expression in an E. coli cydD mutant. Heterologous 
expression of the Mtb cydDC genes restored CbdO biogenesis in the E. coli mutant. 
Using various microbiological approaches, we demonstrated that the mycobacterial 
cydDC was able to revert the stationary phase exit defect, high temperature sensitivity 
and increased oxidative stress susceptibility defects of the E. coli cydD mutant. 
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Collectively, these data provided strong evidence that the mycobacterial cydDC genes 
encode a functional transporter that contributes to periplasmic redox homeostasis. 
Following this, we generated a double deletion mutant of the cydDC operon in M 
smegmatis. We confirmed the genetic integrity of the ΔcydDC strain by Southern Blot 
analysis and proved by absorption difference spectroscopy that this strain is defective in 
the ability to synthesize a functional CbdO, as measured by the lack of a heme d peak 
in membrane preparations from the mutant. In addition, the ΔcydDC mutant displayed 
increased sensitivity to oxidative stress and a reduced ability to exit stationary phase, 
phenotypic defects that were consistent with the lack of CbdO. In summary, this study 
provides the first evidence that loss of the M. smegmatis cydDC genes affects CbdO 
biogenesis. These data also confirm that the CydDC ABC-type transporter most likely 
transports reducing equivalents that allow for maturation of CbdO in the periplasm. 
Collectively, our observations advance the understanding of the mycobacterial electron 
transport chain and provide new evidence to assist in the development of CbdO as a TB 
drug target.  
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1 Introduction 
1.1 Tuberculosis diagnosis and challenges  
Tuberculosis (TB) is a deadly pulmonary disease caused by the notorious human 
pathogen Mycobacterium tuberculosis (Mtb) (Filliol et al., 2002). Although commonly 
associated with chronic lung damage, TB can infect other anatomical sites of the body 
to cause extrapulmonary TB (EPTB) disease such as disease in the lymph nodes (Kim 
et al., 2003). Mtb is a deadly pathogen which has historically afflicted mankind (Krause, 
1927, Keshavjee and Farmer, 2012). Today, Mtb is responsible for an incidence of 9.6 
million TB cases, a mortality rate of 1.4 million cases of pulmonary TB (PTB) and 0.8 
million cases of EPTB cases annually across the globe (WHO, 2016) (Figure 1.1.).  
 
Figure 1.1. Diagrammatic illustration of the world map showing TB hotspots or estimated TB incidences in 2016
by of shades of green. Intense green colour corresponds to a high number of incident cases per 100 000
population annually. The African continent is the worst affected with South Africa (SA) showing the highest
incidence with more than 500 new TB cases recorded each year per 100 000 population. Adapted from WHO
2016.
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Despite being curable, TB continues to claim a massive amount of human life as 
exemplified by the grim statistical figures. Currently, the global TB epidemic is more 
intense in developing countries such as South-Africa (S.A) Figure 1.1. 
Challenges that hamper the successful eradication of TB include numerous socio-
economic factors and lack of innovative interventions. Poverty is a reality for many 
people in third world countries (DOH, 2015, Amaral et al., 1996). As a result, 
establishment of sporadic informal settlements are common and these are marked by 
problems of overcrowding, poor hygiene and malnutrition, which are thought to be key 
drivers of TB infection (DOH, 2015, Millet et al., 2013). Furthermore, developing 
countries have a vast landscape of rural land, where there is additional problems of 
poor sanitation and improper healthcare infrastructure (DOH, 2015, Millet et al., 2013). 
In TB endemic countries with such challenges, the burden of disease has increased to 
unprecedented levels causing rampant loss of human life due to the inability to detect 
and treat source cases timeously (WHO, 2016). As such, better diagnostic tools are a 
crucial necessity. These provide a frame work to better manage cases of outbreaks and 
to initiate sick individuals on chemotherapy (Yagui et al., 2006, Tenover et al., 1993, 
Organization and Organization, 2007). The late 19th and early 20th century saw 
numerous therapeutic innovations to combat TB. For instance, in 1882, Sir Robert Koch 
developed tuberculin as a proposed cure for TB, which saw success as a diagnostic tool 
rather than a curative measure (Trudeau, 1892). Tuberculin has since been repurposed 
for TB diagnosis under the moniker Tuberculin Skin test (TST) (Cooke, 1915). TST is in 
use today as pure protein derivative (PPD) and is at best useful in diagnosing latent TB 
infection (LTBI) (Stavri et al., 2012). Upon suspicion of TB, various tests including chest 
X-ray radiography and sputum smear microscopy are performed to confirm the 
presence of the tubercle bacilli (DOH, 2014, Rabahi et al., 2002).  
In urban settlements, infrastructure is widely available but is outdated. For instance, the 
gold standard for diagnosis in a country such as S.A, with an annual incidence of 450 
000 cases remains solid/liquid culture based methods (DOH, 2014, SSA, 2013). 
Although the latter are specific, they have inherent limitations such as the inability to 
infer drug susceptibility data which is a crucial necessity when initiating sick individuals 
` 
3 
 
on treatment (DOH, 2014). In this regard, the advent of molecular diagnostic tools such 
as GeneXpert and Genotype MTBDRplus has revolutionized TB diagnosis, yielding 
short turnaround times, better sensitivity and providing drug susceptibility data (DOH, 
2014, WHO, 2016).  
Compounded to issues of socio-economic problems, is the lack of new drugs with 
improved killing kinetics. One of the reasons TB eradication has been challenging is the 
lengthy treatment duration, with a high pill burden which contributes to non-compliance, 
ultimately culminating in the emergence of drug resistant strains of Mtb (Adane et al., 
2013). The emergence of such strains has occurred at an alarming rate globally, and 
threatens the eradication of TB (WHO, 2016). Finally, and arguably one of the major 
drivers of the TB epidemic, and deeply entrenched in TB endemic settings, is 
comorbidity with the human immunodeficiency virus (HIV) (Rabahi et al., 2002). The 
dual synergy in individuals with gradual immune decline is deadly, and increases the TB 
incidence toll which enhances the risk of primary infection or reactivation TB (WHO, 
2016). 
1.2 TB Transmission and Pathogenesis 
Mtb is an airborne pathogen, transmitted by the inhalation of infected respiratory nuclei 
expelled from an individual with active PTB disease. In a new host, the infective 
respiratory nuclei travel via respiratory air passages to the upper or lower lobes of the 
lung, where there is elevated oxygen and inherent delayed immunity (Figure 1.2) 
(Balasubramanian et al., 1994).  
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In the lungs, Mtb is rapidly engulfed by dendritic cells (DCs), monocytes and alveolar 
macrophages (Sakamoto, 2012). The initial encounter of Mtb with the host is primarily 
mediated by alveolar macrophages (AMs) (Sakamoto, 2012). AMs recognize and 
interact with pathogen associated molecular patterns (PAMPs) on the surface of Mtb 
through a diverse group of pathogen recognition receptors (PRR) (Bafica et al., 2005, 
Fremond et al., 2004, Ryffel et al., 2005). Most frequently, host pathogen interaction 
occurs through toll like receptors (TLRs), which stimulate a chronic pro-inflammatory 
cytokine response that is growth restrictive for the bacilli (Bafica et al., 2005). This 
interaction also establishes a protective niche, wherein Mtb persists indefinitely in a 
metabolically quiescent state. Upon phagocytosis by alveolar macrophages, Mtb has 
the capacity to replicate unchecked intracellularly, inducing necrotic lesions that 
Transmission
Entry and proliferation in 
new host
Macrophage 
infection
Granuloma 
formation
Granuloma 
maturation
lymphocytes
Necrosis of 
granuloma and 
extracellular 
replication
Figure 1.2. Schematic illustration of TB transmission and pathogenesis. Adapted
from Cambier et.al., 2014. Infection is acquired when an uninfected person inhales
respiratory nuclei containing Mtb. In the new host, Mtb replicates until encountered by
resident alveolar macrophages (AMs) in the lung. The formation of an intact granuloma
begins until it matures to form a barrier of containment. The granuloma collapses in an
event of gradual immune decline releasing the Mtb which may remain localised or
hematogenously disseminated. In the cycle of infection, Mtb is expectorated in the
process of coughing to infect a new host.
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ultimately result in the demise of the Mtb laden macrophages (Vergne et al., 2005, 
Ferrari et al., 1999, Chen et al., 2006). Necrosis results in death of most bacteria 
(Figure 1.2).  
In immunocompetent individuals, bacterial cells that survive the respiratory burst are 
rapidly engulfed by monocytes (Gercken et al., 1994, Shi and Pamer, 2011). Monocytes 
induce trafficking of various cell types to the site of infection, establishing a highly 
structured barrier known as the granuloma to aid in containment of infection (Gonzalez-
Juarrero et al., 2001). The lesion at the initial site of implantation is called the ghon 
focus. Tubercle bacilli may traffic via the lymphatic system to regional lymph nodes prior 
to the formation of the granuloma, causing lymphadenitis and granulomatous 
lymphaginitis. These sites colonized by Mtb are collectively referred to as the Rankes 
complex. Extensive dissemination of Mtb can occur via the blood stream during these 
early stages of infection. Approximately, 90% of infected immunocompetent individuals 
can resolve these lesions without progressing to active TB disease. However, in 10% of 
infected individuals, it is suspected that a high bacterial burden, immune decline or 
infection with a highly virulent strain results in primary progressive disease (Comstock, 
1982). In individuals that do not clear the infection but also do not display symptoms, 
the tubercle bacilli are postulated to exist in a metabolically quiescent state. Studies of 
gene expression have shown that under these conditions, Mtb shuts down key anabolic 
processes, down-regulates expression of most non-essential genes and exists in a non-
replicative state (Eoh and Rhee, 2013). This chronic state is diagnosed as LTBI which 
afflicts 2 billion individuals worldwide (WHO, 2015). In this state, a patient has no clinical 
manifestation of the disease and can exist in this condition for a life time, barring an 
event that leads to health deterioration (Corbett et al., 2003). In the event of gradual 
health decline, which occurs between 5-10% of individuals who relapse, the highly 
structured granuloma steadily collapses and forms a caseous granuloma which 
eventually liquefies to form a cavitary granuloma (Tufariello et al., 2003). Herein, Mtb is 
able to escape to other anatomical sites and cause miliary TB disease or cause further 
lung damage (Corbett et al., 2003). This is diagnosed as secondary TB disease and is 
mainly characterized by symptoms ranging from unexplained weight loss, to dyspnea 
(Sagbakken et al., 2008). Approximately 80% of clinical cases originate from secondary 
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TB disease (Garay, 1996). Moreover, immune compromised individuals are unable to 
recruit more immune cells to the site of infection due to T-cell depletion and in such 
cases, Mtb causes debilitating EPTB disease which accounts for 15% of secondary 
reactivation cases (De Backer et al., 2006). These complex clinical presentations in 
both immune competent and immune compromised individuals render the disease 
difficult to treat and manage. 
1.3  Treatment and drug resistance 
TB is a curable but challenging disease to treat, requiring protracted treatment with 
combinatorial therapeutic drugs (Maher et al., 2003). This is evidenced by the fact that 
in the post antibiotic era, TB is still associated with a high mortality rate. In S.A alone, 
TB claims just under 65 000 lives each year (SSA, 2013). Since the discovery of 
rifampicin (RIF) in 1957, multiple drug treatment was implemented for the management 
of drug susceptible TB due to high relapse cases and the emergence of resistance 
when mono-drug therapy was administered (Keshavjee and Farmer, 2012, Sensi, 
1983). To increase cure rates and prevent the soaring emergence of drug resistant 
strains, the WHO implemented Directly Observed Short Course Therapy (DOTS) were, 
drugs are administered to patients under the direct supervision of a health care 
professional (WHO, 1995). At present, the standard treatment protocol for short course 
combination therapy for drug susceptible TB in SA includes a two-month intensive 
phase of RIF, isoniazid (INH), ethambuthol (EMB) and Pyrazinamide (PZA), followed by 
four months continuation phase of RIF and INH (DOH, 2014).  
EPTB is associated with significant fatalities globally and treatment involves the same 
regimen with the same duration as PTB for the drug intensive phase, while the 
continuation phase can be extended up to seven months (DOH, 2014). Moreover, the 
treatment of TB is complicated by multiple therapeutic complexities including but not 
limited to a high pill burden, poor drug penetration to certain body compartments and 
adverse drug-drug interactions. Adding to this, is the pool of approximately 2 billion 
individuals with LTBI, which is difficult to treat and has rendered TB nearly impossible to 
eradicate. Approximately 10% of this vast population stands a life time risk of relapsing 
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to active PTB disease, of which 15% will develop EPTB (WHO, 2016). INH preventative 
therapy has been proven effective and is the only wide-spread therapy for LTBI (WHO, 
2016). INH therapy is difficult to scale and needs protracted treatment durations, 
However, nine months can generally suffice to achieve bacterial clearance (Cohen et 
al., 2006). Comorbidity with HIV is a major factor that threatens the successful 
eradication of TB especially in the context of the 2 billion individuals with LTBI. The drug 
antagonism between anti-TB drugs and antiretroviral therapy (ART) is generally not well 
understood. However, it has been demonstrated that RIF gradually decreases the 
plasma concentration of nevirapine and efavirenz (Ngaimisi et al., 2011). This may 
confer resistance to ART therapy due to exposure of HIV to sub-lethal drug 
concentrations during therapy. As TB is an opportunistic disease in HIV infected 
individuals, resistance to ART results in the gradual dissolution of the solid granuloma 
through depletion of the CD4 T-cell population, which constitute the granuloma wall. 
This leads to poor containment of TB disease in the lungs of HIV infected individuals 
creating numerous therapeutic challenges. 
The rapid emergence of drug resistant TB strains is unequivocally one of the major 
drivers of the TB epidemic (WHO, 1993). Multidrug resistant TB (MDR-TB) is defined as 
TB that is resistant to either RIF or INH (WHO, 2016). Cases of MDR-TB are a common 
occurrence globally, with WHO estimating 450 000 incident cases and approximately 
170 000 deaths associated with MDR-TB in 2012 alone (WHO, 2013). MDR-TB is more 
expensive to treat and requires protracted treatment with toxic drugs (WHO, 2016). This 
has created an urgent need for new drugs. Recently, the food and drug administration 
(FDA) approved Bedaquiline, the first new TB drug in 40 years, for the treatment of 
MDR-TB (Mahajan, 2013). Patients with MDR-TB are elevated to a combinatorial 
regimen of fluoroquinolones and other second line drugs. In addition to MDR-TB, 
extensively drug resistant TB (XDR-TB) has been reported. This form of drug resistant 
TB comprises MDR-TB, with the added resistance to fluoroquinolones and 
aminoglycosides (Daniel et al., 2013). The prevalence of these composite forms of drug 
resistance in the clinic demonstrates that Mtb has the intrinsic ability to develop 
resistance to anti-TB agents. This can occur through multiple mechanisms such as the 
ability to extrude drugs using dedicated transport systems (Calgin et al., 2013). 
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Alternatively, stable chromosomally encoded resistance is acquired through exposure to 
sub-lethal concentrations of antimicrobial agents (Black et al., 2014). This underscores 
the need to develop new drug that have novelty in their action. 
1.4  New drugs for TB 
TB represents a serious challenge to global health. In recent years, various factors 
some of which have been described in the previous sections have contributed to TB 
resurgence with increased virulence due to the emergence of MDR strains. As a result, 
substantive effort has been directed towards the discovery of novel drugs to add to the 
existing antibiotic arsenal (Neres et al., 2012). New lead antibiotics that have resulted 
from these endeavors are described next. 
1.4.1 Benzothiazinone  
Benzothiazinone (BTZ) represents a group of new drugs in the developmental pipeline 
for TB treatment. BTZ043 a lead compound, is presently in the late preclinical stages of 
development (Lienhardt et al., 2012). BTZ043 shows a minimal inhibitory concentration 
(MIC) of 1 ng/mL against Mtb, making it significantly more potent than any of the 
currently used drugs. BTZ043 targets the DprE1 component of the mycobacterial 
decaprenylphosphoryl-β-D-ribofuranose-2′-epimerase encoded by the dprE1/dprE2 
operon (Makarov et al., 2009). These genes are essential for growth of Mtb and M. 
smegmatis (Crellin et al., 2011, Sassetti and Rubin, 2003). Expression of this operon is 
pre-requisite to carry out the epimerization reaction of decaprenylphosphoryl-β-D-
ribofuranose (DPR) into decaprenylphosphoryl-β-D-arabinose (DPA)(Mikušová et al., 
2005). DPA is the sole monomer for the synthesis of the arabinan moiety of the 
mycobacterial cell wall, whose unique composition renders mycobacteria insensitive to 
a number of antibiotics (Wolucka, 2008). Furthermore, all Mtb clinical isolates tested so 
far, from drug sensitive to all forms of MDR cases, were susceptible to BTZ043, making 
this drug a promising candidate for the treatment of all forms of TB (Wolucka, 2008). 
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1.4.2 Q203 
Q203 is a lead compound belonging to a class of imidazopyridine amides currently 
under clinical development (Pethe et al., 2013). Q203 shows remarkable activity in the 
nanomolar range with MICs of 2.7 nM/mL for Mtb (H37Rv) and 0.28 nM/mL in 
macrophages. The cellular target for Q203 is the bc1/aa3 oxidoreductase, which is 
encoded by the qcrCAB operon (Pethe et al., 2013). Inhibition by Q203 is specific to 
Mtb and the same killing effect was observed against all forms of MDR-TB in clinical 
isolates. Q203 is easy and affordable to synthesize, which is an added benefit for low-
income TB endemic countries. This candidate showed remarkable safety with no signs 
of clinical toxicity at high dosage in mice (Pethe et al., 2013). Q203 also displayed 
remarkable stability, suggesting that it might achieve good exposure levels in the blood 
(Pethe et al., 2013). As a result, Q203 is an ideal drug candidate, which also displayed 
compatibility with other TB drugs (Pethe et al., 2013). 
1.4.3 Bedaquiline 
As mentioned previously, Bedaquiline (BDQ) is the first drug in 4 decades to receive 
accelerated approval by the FDA (Cohen, 2013). BDQ belongs to the arylquinolone 
class of drugs and although it displayed delayed killing kinetics in the initial days of 
administration. It is efficacious in bacterial clearance during protracted treatment. The 
cellular target of BDQ is the C-ring of the F1F0 ATP synthase. BDQ achieves bacterial 
killing by blocking the C-ring, leading to intracellular ATP depletion, periplasmic redox 
imbalance and subsequent death of bacteria (Sacksteder et al., 2012). BDQ is only 
approved for treatment of MDR-TB and has also displayed synergy with other anti-
tubercular drugs (Sacksteder et al., 2012). These advances are anectodal proof that 
bacterial electron transport chains (ETCs) are relatively unexplored biological pathways 
with untapped potential for the identification of novel drug targets. This hypothesis forms 
the basis of the work presented in this MSc and will be explored further below.  
1.5 The Electron transport chain 
The increase in drug resistance and therapeutic complexities that present with treating 
HIV-TB co-infected individuals has necessitated an urgent need for new drugs, with 
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novel modes of actions. Moreover, in Africa, to succeed in the fight against TB, 
solutions that are tailored to the local needs are required. For this, this study explores 
the mycobacterial ETC, a new and tractable area of research in mycobacteria for the 
identification and validation of new drug targets. The following section reviews the 
literature of the components of the aerobic branch of the mycobacterial ETC, their role 
in electron transport, and their validation in drug development. 
1.5.1 The aerobic branch of the mycobacterial ETC 
Mycobacteria occupy diverse and dynamic ecological niches which has prompted 
various evolutionary adaptions for survival. These adaptations include utilization of their 
branched ETC (also referred to as the respiratory chain), which endows them with the 
ability to optimize ATP yield in adverse and constantly changing environments. The 
modular nature of the ETC allows fine tuning of its components to best suit prevailing 
growth conditions and the availability of electron donors or electron acceptors, Figure 
1.3.  
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During different stages of TB pathogenesis, oxygen availability may vary widely, under 
aerobic conditions. To adapt to this, Mtb couples substrate catabolism to respiration 
using two terminal oxidases (with different affinities to oxygen), while in the absence of 
oxygen, electron transport is re-routed to anaerobic terminal oxidases (Figure 1.3). The 
ETC of bacteria is located in the plasma membrane and comprise a series of enzymes 
and enzyme complexes that catalyze coupled oxidation/reduction reactions. 
1.5.2 The composition of the mycobacterial aerobic electron transport chain  
The mycobacterial ETC comprises enzymes that vary in metal cofactor and heme 
composition in their catalytic center (Figure 1.4).  
MK-9 Pool
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Figure 1.3. Schematic illustration of the branching and flexibility of Mtb showing electron donors and acceptors used by Mtb
during respiration. Adapted from Hurdle et al., 2011. Electrons enter the ETC via NADH dehydrogenase (NDH) and succinate
dehydrogenase (SDH) and are transferred to menaquinone (MK-9). Under aerobic conditions, electrons are transferred to
oxygen via cytochrome bc1 reductase-cytochrome caa3 oxidase supercomplex (CcO) or the cytochrome bd oxidase (CbdO).
Electrons can be transferred to nitrate and fumarate, when these are available, via the nitrate and fumarate reductases.
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Central to the ETC, is the lipophilic menaquinone pool, which is reduced by different 
dehydrogenases that in turn extract energy via oxidation of cytoplasmic electron donors 
(kana, 2009). This process is linked to the generation of periplasmic proton motive force 
(PMF) through proton translocation (kana, 2009). Due to the branching of the ETC, the 
menaquinol pool is oxidized by one of the terminal oxidases depending on oxygen 
tension (kana, 2009). The electrons are finally relayed to oxygen, which is the final 
electron acceptor under aerobic conditions. When the proton concentration in the 
periplasm is greater than in the cytoplasm, protons move through the membrane bound 
ATP synthase to synthesize ATP via oxidative phosphorylation (Chance and Williams, 
1956).  
The respiratory chain of Mtb has recently emerged as a previously untapped source for 
the identification and validation of new antitubercular drug targets. In the section below, 
the individual components of the aerobic branch of the mycobacterial ETC are detailed 
Fumarate
Figure 1.4. Schematic representation of the mycobacterial aerobic ETC. Electron flow is initiated by the oxidation of the
reducing equivalents, NADH by NADH dehydrogenase (ndh-1) which is associated with the translocation of protons (H+)
across the cytoplasm and succinate dehydrogenase (sdh) respectively. The accumulation of protons in the periplasm builds
a proton gradient which is used to generate ATP by the ATP synthase. The electrons that are released, are relayed through
the lipid soluble menaquinol pool to one of the two terminal electron acceptors cytochrome c Oxidase (CcO) cytochrome bd
Oxidase (CbdO) expressed under aerobic or hypoxic conditions respectively. Within the CbdO, b558, b595 and d represent
heme molecules. Adapted from Hurdle et al., 2011.
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further in terms of their biochemical properties, their role in electron transport, ATP 
synthesis and their potential as promising drug targets. 
1.6 NADH dehydrogenase 
Electron donors such as NADH and succinate are products of other metabolic pathways 
and enter the ETC of bacteria and mitochondria for oxidative metabolism. The initiation 
of electron transport depends on the action of quinone oxidoreductases, such as the 
NADH dehydrogenase and succinate dehydrogenase (Black et al., 2014). There are 
three types of NADH dehydrogenases in bacteria including the sodium pumping NADH 
dehydrogenase (NQR), the proton pumping NADH dehydrogenase (NDH-1) and non-
proton pumping NADH dehydrogenase (NDH-2) (Kerscher et al., 2007). This 
classification is based principally on differences in structural complexity and their 
efficiency in energy conservation. 
1.6.1 NDH-1 
The type I NDH is structurally more complex and dynamic than the other two families of 
NADH dehydrogenases. In bacteria, NDH-1 is encoded by a 14 sub unit nuoA-N operon 
which represents the ortholog of the 45 subunit mitochondrial NADH dehydrogenase 
(Kerscher et al., 2007, Sazanov and Hinchliffe, 2006). Also known as complex I, this 
enzyme serves as the main gated channel for electrons into the ETC through the 
oxidation of its substrate, NADH, shown in Figure 1.5 (Kerscher et al., 2007).  
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Complex I is present in various species of mycobacteria, with an additional role of 
recycling the NAD+ cofactor to ensure that other metabolic pathways are not negatively 
affected by an imbalance in the NADH/NAD+ redox couple. NDH-1 is considered as the 
most basic form of the enzyme required to execute its holistic function. This includes 
NADH oxidation, quinol reduction and proton translocation (Kerscher et al., 2007). 
NuoB-G are cytoplasmic proteins which are associated with the membrane bound 
subunits and are responsible for the oxidation of NADH. NuoA, H, I J, K, L, M, and N 
are located in the lipid bilayer, with several predicted transmembrane domains that aid 
in the translocation of protons across the cytoplasm (Russell and Cook, 1995, Weinstein 
et al., 2005, Kerscher et al., 2007, Miesel et al., 1998). In terms of energetics, the 
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Figure 1.5. Diagrammatic illustration of the alternate forms of NADH dehydrogenase in Mtb.
NDH-1 is involved in energy conservation through proton translocation across the cytoplasm.
NDH-2 is the preferred alternate form in Mtb although it lacks proton pumping activity. In both
cases type I and type II NDHs, facillitate initiation of the electron transport chain through the
oxidation of NADH. This reaction results in recycling of redox intermediates contributing to
redox homeostasis. Adapted from Sazanov and Hinchliffe, 2006.
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release of two electrons during NADH oxidation is coupled to the translocation of four 
protons, thus contributing to the conservation of energy in the form of a proton gradient 
in the periplasm (Figure 1.5). Proton translocation occurs through iron-sulfur (Fe-S) 
clusters that can interact with molecular oxygen. This Interaction contributes to the 
inherent low levels of oxidative radicals generated by the respiratory chain. Surprisingly, 
the activity of Complex I is completely abolished in M. leprae with the nuoN pseudo 
gene being all that remains of Complex I (Sassetti et al., 2003, Cole et al., 2001). 
Consistent with this, growth of Mtb in the In vitro hypoxic Wayne model has 
demonstrated that Complex I is dispensable for growth and is not required for 
persistance (Rao et al., 2008). The role of Complex I in proton translocation was 
determined experimentally in E. coli, and Klebsiela pneumonia through inhibition with 
piericidin A and the use of pH sensitive dyes (Stolpe and Friedrich, 2004). In Mtb 
infected macrophages, NuoG which encodes a subunit of Complex I has been 
implicated in the inhibition of apoptosis (Velmurugan et al., 2007). These results 
implicate complex I, which is highly expressed during anaerobic conditions in E. coli and 
Mtb, in virulence (Unden and Bongaerts, 1997, Shi et al., 2005). 
1.6.2 NDH-2 
Type II NDH also known as the alternative NADH dehydrogenase, is a single subunit 
flavoprotein that lacks the ability to translocate protons (Kerscher et al., 2007) (Figure 
1.5). Besides its role in recycling NAD+, which is a cellular oxidant in bacteria, this 
simple enzyme carries out the oxidation of NADH and reduces the quinone pool 
(Kerscher et al., 2007). NDH-2 is also present in mycobacteria and seems to be the 
preferred NADH:menaquinone oxidoreductase in several mycobacterial species. This is 
evidenced by the observation that the genome of M. leprae, which has undergone 
extensive reduction, retains a functional NDH-2 for oxidation of NADH (Sassetti et al., 
2003, Cole et al., 2001). Furthermore, NDH-2 activity in M. smegmatis is 5-fold higher 
than NDH-1 activity (Miesel et al., 1998, Vilcheze et al., 2005). This enzyme is 
ubiquitous in prokaryotes and its expresion in E. coli occurs mainly under aerobic 
conditions (Unden and Bongaerts, 1997, Pereira et al., 2004). NDH-2 is present in Mtb 
in alternate forms as Ndh and NdhA (Pereira et al., 2004). Optimal In vitro growth of Mtb 
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requires the expression of NDH-2 while its expression in immune compromised mice 
shows that it is not required for pathogenesis (McAdam et al., 2002, Sassetti and Rubin, 
2003). The presence of two forms of NDH-2 does not seem to be due to genetic 
redundancy as one copy appears to be more important than the other (Lin et al., 2011, 
Griffin et al., 2011). NDH-2 enzymes are the simplest NADH dehydrogenases and 
encode a short polypeptide (463 amino acids) with two GXGXXG motifs for NADH 
oxidation and flavin (FAD) binding for menaquinone reduction (Melo et al., 2004, 
Weinstein et al., 2005). Type II NDHs have been explored for drug development by 
screening a variety of inhibitors. As proof of the principle, In vitro screening studies with 
phenothiazines demonstrated mycobactericidal activity with these compounds, albeit at 
very high minimum inhibitory concentrations (MICs). Chlorpromazine and other related 
drugs have also been shown to have bactericidal effect against MDR-TB (Amaral et al., 
1996). For instance, trifluoperazine (TPZ), a derivative of phenothiazines, displayed 
activity in a macrophage model and compatibility with other antitubercular drugs (Reddy 
et al., 1996). Mechanistic studies also unraveled the mode of inhibition of 
phenothiazines, which includes uncompetitive inhibition of Complex I (Yano et al., 
2006). The consequences of uncompetitive inhibition in mycobacteria may include an 
imbalance in the redox carriers (NADH/NAD+ couple), reduced electron flux and 
reduced PMF resulting in a decrease in ATP yield (Katoch et al., 1998). These 
advances illustrate the unique mycobactericidal activity of phenothiazines through 
disruption of ATP synthesis and impeding cofactor recycling. 
1.7 Succinate dehydrogenase (SDH) 
Also known as Complex II, SDH is also capable of initiating the ETC in both bacteria 
and mitochondria. SDH is a flavoprotein with a dual role in the ETC and the tricarboxylic 
acid cycle (TCA) through the oxidation of succinate to fumarate and the concomitant 
transfer of two electrons to the menaquinone pool to generate menaquinol (Black et al., 
2014). Quinol fumarate reductase also known as fumarate dehydrogenase (FDH), is an 
enzyme that is functionally and structurally similar to the SDH, and for this reason, it is 
annotated as Complex II as well (Cecchini et al., 2003). During anaerobic conditions, 
FDH catalyzes the oxidation of quinol to reduce fumarate to succcinate (Cecchini et al., 
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2003). SDH are generally multi-subunit enzymes that do not couple succinate oxidation 
to proton translocation (Figure 1.6).  
 
In mycobacteria, SDH is present as SDH-1 and SDH-2. SDH-2 is encoded by sdhA, 
sdhB, sdhC and sdhD. Subunits of sdhA and sdhB are hydrophillic and form the 
cytoplasmic domains of SDH-2. SdhA contains the substrate binding site and the FAD 
prosthetic group (Cecchini et al., 2003, Lancaster, 2002). Subunit B of SdhB contains 
three distinct Fe-S clusters for electron transport and is sandwiched between SdhA and 
the membrane. SdhC and SdhD constitute integral membrane domains with variable 
number of b-type cytochromes and quinone binding sites, which are responsible for the 
two electron transfer and subsequent reduction of menaquinone (Cecchini et al., 2003, 
Lancaster, 2002). The reaction entailing the oxidation of succinate and the concomittant 
reduction of menaquinone is biochemically unfavourable due to the low reduction 
potential of menaquinone relative to that of the oxidation of succinate. This reaction 
would result in the reversal of electron transfer. Thus to circumvent this, it is proposed 
that the membrane reduction potential is used to drive the reaction forward, where the 
Figure 1.6. Schematic illustration of succinate dehydrogenase also known as Complex II. In Mtb
SDH is encoded by four subunits: SdhA, SdhB, SdhC and SdhD. SDH reduces the menaquinol pool
but is not associated with energy conservation through proton translocation. Adapted from (Huang
and Millar 2013.)
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electrons from the cytosol pass through cytochrome b via the Fe-S clusters until 
deposited into the menaquinone pool (Schirawski and Unden, 1998). Alternate forms of 
the SDH enzyme are differentially expressed depending on the culture conditions. For 
instance, SDH-1 was upregulated 4-fold under energy limiting conditions while SDH-2 
was significantly downregulated under the same conditions (Berney and Cook, 2010). 
Conversely, SDH-2 was upregulated 2-fold while SDH-1 was significantly 
downregulated under high oxygen tension (Berney and Cook, 2010). Therefore, it is 
tempting to speculate that these expression profiles implicate SDH-1 as a dedicated 
enzyme, which is adapted to functioning at high oxygen tension while its counterpart 
essentially functions as FDH during hypoxia. The SDH complex is dispensable for 
growth in Mtb (Sassetti et al., 2003) and as such, the true role of this enzyme is not 
thoroughly understood and requires elucidation. 
1.8 Menaquinone 
Isoprenoid quinones form part of bacterial plasma membranes (Lester and Crane, 1959) 
and are pivotal in electron transport, oxidative phosphorylation and possibly active 
transport (Dunphy and Brodie, 1971, Redfearn, 1967, Taber, 1980). Quinones are 
lipophillic proteins that facilitate electron transport in the inner membrane during energy 
metabolism (Hedrick and White, 1986) and have been used as taxonomic markers in 
bacteria (Bragg and Hou, 1967). There are various types of quinones which differ in 
number and side chain position of the encoded structural subunits. Ubiquinones, 
menaquinones and desmethyl menaquinones are widespread bacterial quinones 
(Hedrick and White, 1986). Ubiquinones predominate in eukaryotes and some gram 
negative bacteria while menaquinones are widespread among gram positive, gram 
negative bacteria and archaeabacteria (Hedrick and White, 1986). Desmethyl 
menaquinones are not common and have been reported mainly in pathogenic 
enterobacteria (Hedrick and White, 1986). Mycobacteria employ MK, an inner 
membrane confined lipid soluble electron carrier for electron transport (Yassin et al., 
1988). MK is a derivative of 2-methyl-1.4-naphthoquinone and contains variable lengths 
of repeating units of isoprenoids and its biosynthesis entails a range of enzymes. MK 
biosynthesis in Mtb is mediated by at least six genes encoded by the menABCDEH 
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gene cluster (Cole et al., 2001). Mtb and M. smegmatis rely exclusively on MK-9 as a 
redox intermediate (Collins and Jones, 1981, Collins et al., 1977, Yassin et al., 1988). 
MK-9 is reduced by both the NADH dehydrogenase and SDH to form menaquinol. In 
the presence of oxygen, the menaquinol pool terminates at one of the two terminal 
oxidases which subsequently oxidizes the reduced menaquinol pool (Yassin et al., 
1988). The enzymes involved in the biosynthesis of MK-9 represent ideal drug targets 
for TB drug development as MK-9 is not homologous to the mitochondrial ubiquinone 
electron carrier. Hence, cross-reactivity with the human enzymes is not expected. 
1.9 Cytochrome bc1/aa3 super complex 
Bacterial oxidases catalyze approximately 90% of molecular oxygen reduction 
estimated to occur in the biosphere (Norman et al., 1965). Unlike the mitochondrial ETC 
which has a single terminal cytochrome c oxidase, bacterial respirasomes are 
branched, harboring distinct terminal oxidases for the reduction of electron acceptors 
under specific conditions. Bacterial terminal oxidases are generally grouped into two 
super families; the heme copper oxidase (HCO) and the cytochrome bd-type oxidase 
super families. Whilst the latter will be discussed in more detail in the following section, 
HCOs are by far the largest super family of respiratory oxidases (García-Horsman et al., 
1994). HCOs are ubiquitous in nature, virtually present in all domains of life. This super 
family also encompasses terminal oxidases that generally exist in complexes with other 
enzymes and collectively function in unison (García-Horsman et al., 1994). HCOs are 
characterized by the presence of multiple redox centers such as the presence of 
different types of cytochromes, Rieske Fe-S clusters (carried in the reductase 
component of the supercomplex) and multiple subunits encoded by the oxidase 
component of the supercomplex (Kitagawa and Ogura, 2007, Calhoun et al., 1994). 
Furthermore, HCOs are optimally expressed under normoxic growth conditions and 
couple quinol oxidation to the generation of a proton gradient across the cytoplasmic 
membrane (Matsoso et al., 2005). Their catalytic site, where oxygen reduction occurs, 
contains a copper atom and a cytochrome composed of a b type heme molecule. This 
binuclear catalytic center is notably different from the hetero-di-heme catalytic 
composition of the bd-type oxidase (Matsoso et al., 2005, García-Horsman et al., 1994). 
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The diagrammatic representation of the HCO found in Mtb, that is the Cytochrome bc1 
reductase-cytochrome c oxidase super complex, comprising cytochrome bc1 reductase 
and cytochrome c oxidase components, is shown (Figure 1.7).  
 
In Corynebacterium glutamicum, the cytochrome bc1 reductase is responsible for the 
oxidation of the menaquinol pool, a reduced electron carrier in gram positive bacteria 
(Megehee et al., 2006, Megehee and Lundrigan, 2007, Graf et al., 2016).The 
cytochrome bc1 reductase of C. glutamicum and that of mycobacterial species is 
encoded by the qcrCAB operon (Pethe et al., 2013, Matsoso et al., 2005, Niebisch and 
Bott, 2001) Figure 1.7. Cytochrome c oxidase (CcO) is separately encoded by the 
ctaBCDEF operon (Figure 1.7) (Pethe et al., 2013, Matsoso et al., 2005, Niebisch and 
Bott, 2001). Bioinformatic analysis of the bc1 reductase and CcO by Black and co 
workers revealed that both these components are conserved across the mycobacteria 
(Black et al., 2014, kana, 2009). The qcrC gene encodes a unique cytochrome 
comprising two c-type hemes with quinol binding sites, a typical feature of 
actinomycetes (Matsoso et al., 2005). The qcrB gene encodes cytochrome b and qcrA 
Figure 1.7. Cytochrome bc1/aa3 super complex. This oxidoreductase is composed of two
enzyme complexes, namely: cytochrome bc1 reductase and cytochrome c oxidase (CcO). The
bc1 complex is encoded by the qcrCAB operon while CcO is encoded by the ctaBCDEF operon.
This super complex serves as the main aerobic branch for respiration under high oxygen
tension. It catalyzes the reduction of oxygen to water and conserves energy through the
formation of a proton motive force (PMF) in the process. Adapted from Graf et al., 2016.
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encodes the Fe-S cluster subunit. In CcO, ctaB encodes an assembly factor while ctaC-
F encode subunit II, III, IV and V respectively (Matsoso et al., 2005, Black et al., 2014), 
which form the transmembrane domains for proton translocation and a catalytic redox 
center comprising a copper ion, a high spin b-type heme, a tyrosine residue coordinated 
to histidine that in turn binds the heme for the reduction of dioxygen to water (Sousa et 
al., 2012). Due to the high degree of homology of the bc1 complex in mycobacteria and 
in C. glutamicum, it has been proposed that the same structural integrity is preserved in 
Mtb (Niebisch and Bott, 2001) and M. smegmatis (Kana et al., 2001). Indeed, the 
presence of the bc1 complex was since verified by two studies in Mtb and M. smegmatis 
(Matsoso et al., 2005, Megehee et al., 2006). Since this terminal oxidase plays a vital 
role in the growth of Mtb (Sassetti et al., 2003, Matsoso et al., 2005), it has been 
targeted for drug development by Q203 for which clinical trials are underway (Pethe et 
al., 2013, Kang et al., 2014). Serious growth defects have been reported upon 
inactivation of the bc1 complex in M. smegmatis (Matsoso et al., 2005). Furthermore, 
disruption of this complex was accompanied by an increase in the expression of 
cytochrome bd oxidase (CbdO), suggesting that the two aerobic branches of the ETC in 
Mtb can accommodate changes in electron flux. Conversely, the opposite was not 
observed when CbdO was inactivated by targeted disruption (Megehee and Lundrigan, 
2007). These advances in targeting terminal respirisomes involved in the production of 
ATP comprise a promising strategy for the eradication of TB. This MSc further explores 
the possiblity of targetting the assembly of the CbdO for TB drug development. For 
further context, the relevant literature pertaining to CbdO is discussed below. 
 
 
1.10 Cytochrome bd Oxidase (CbdO) 
1.10.1 Distribution and evolution 
CbdO is widely distributed among prokaryotes, moreover, its distribution seems to be 
limited to prokaryotes that respire anaerobically (Brochier-Armanet et al., 2009, Baughn 
and Malamy, 2004). It has been shown that prokaryotes can encode one or more CbdO 
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family member and as a rule, microorganisms that encode multiple members of CbdO 
also harbor at least one HCO reductase (Borisov et al., 2011). CbdO is more common 
in proteobacteria and actinobacteria and has also been detected in 18 other bacterial 
phyla (Brochier-Armanet et al., 2009). CbdO is an ancient enzyme with a progenitor in 
both bacteria and the archaea. This unique enzyme may have originated in bacteria and 
acquired through horizontal gene transfer by various members of the archaea (Brochier-
Armanet et al., 2009).  
1.10.2  Genetics and physiological role 
1.10.2.1 The mycobacterial CbdO in relation to other bacteria 
The ETC of mycobacterial species like of many bacteria terminate at the aa3-type CcO 
or CbdO under aerobic conditions (Kana et al., 2009). The expression level of each 
terminal oxidase is dictated by O2 abundance. For instance, CcO is highly active under 
oxystatic conditions whilst the expression of CbdO increases under microaerophillia 
(Kana et al., 2001, Aung et al., 2014, Matsoso et al., 2005). This is consistent with 
expression kinetics in Azotobacter vinelandii and Klebsiella pneumoniae, where CbdO 
deficiency severely impairs nitrogen-fixing ability under microaerobic conditions (Kelly et 
al., 1990, Juty et al., 1997, Edwards et al., 2000). As with CcO, CbdO functions as a 
terminal electron acceptor under aerobic conditions and generates 2 moles of water for 
each mole of O2 reduced (Kana et al., 2009). This process is associated with 
conservation of energy in the form of periplasmic PMF which is later used by the rotary 
ATP synthase to generate metabolic energy in the form of ATP (Kana et al., 2009). In 
M. smegmatis, two subunits encode CbdO, the larger subunit I (53.96 KDa) encoded by 
the cydA gene and the smaller subunit II (37.95KDa) encoded by the cydB gene (Kana 
et al., 2001) (Figure 1.8). Inactivation of these subunits by mutagenesis results in the 
spectroscopic loss of a diagnostic peak associated with CbdO biogenesis (Kana et al., 
2001). It has been established that subunit I is axially coordinated to a low spin b-type 
hemoprotein (b558) by Histidine and Methionine residues at position 186 and 393 
respectively (Osborne and Gennis, 1999).  
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Subunit II is bound by two high spin hemoproteins, namely b595, a b-type hemoprotein, 
and a chlorin type- d hemoprotein, which are coordinated by Histidine and Glutamine 
residues at position 19 and 99 respectively (Borisov et al., 2008, Yang et al., 2007). In 
vitro studies reveal that in M smegmatis, CbdO is upregulated more than 50-fold in 
response to 0.6% air saturation with increased generation time (Berney and Cook, 
2010). Also, it has been established that the expression of the structural genes 
increases at least 3 fold in response to a decrease in O2 saturation between 5 to 0.5% 
(Kana et al., 2001). Furthermore, In vivo studies reveal that in Mtb, transcript levels of 
both cydA and cydC increase during chronic infection in mouse lungs and that 
mutations in cydC result in impaired growth of Mtb in mice (Shi et al., 2005). Additionally 
Mtb mutants of cydC exposed to INH therapy have a growth defect during persistence 
Figure 1.8. Schematic illustration of Cytochrome bd Oxidase (CbdO) one of the terminal
branches of aerobic respiration in Mtb. CbdO comprises two structural proteins namely CydA and
CydB but requires the presence of the unlinked cydDC operon which encodes a transporter
necessary for biogenesis of a functional CbdO. CbdO catalyzes the reduction of oxygen to water
and lacks proton pumping activity. The CydDC function as exporters of thiol (GSH) compounds
which reduce periplasmic proteins to restore redox homeostatic poise in the periplasm. Adapted
from Pittman et al 2002.
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(Dhar and McKinney, 2010). All of these observations point to CbdO being important for 
virulence of Mtb. 
Notably in M. smegmatis, biogenesis of a functional CbdO under microaerophillia 
requires the synthesis of two other proteins downstream of the cydAB operon, namely 
the CydD and CydC transporters (Aung et al., 2014). The cydDC genes are transcribed 
as an operon, separately from the cydAB operon. In 2014, Aung and co-workers 
mapped the transcriptional start site (TSS) of cydD and identified a genetic region -68 
bp upstream of the TSS, essential for transcriptional regulation of the cydDC operon 
(Aung et al., 2014). Consistent with this, bioinformatics analyses from this MSc reveals 
a spacer region of 95 bp between cydB and cydD. This DNA spacer region potentially 
represents binding sites for transcriptional regulation of the cydDC operon. The 
regulatory mechanism for the cydAB operon has been reported both for Mtb and M. 
smegmatis and is facilitated by the cyclic AMP receptor protein (Aung et al., 2014). 
Regulation of the cydDC operon is yet to be reported in any mycobacterial species. 
However, it is likely that regulation is facilitated by the two component system ArcAB 
and the FNR system as in E. coli (Iuchi and Lin, 1991, Fu et al., 1991). The two 
component ArcAB system functions by responding to changes in O2 tension (Iuchi and 
Lin, 1991). Consistent with this, the M. smegmatis cydDC operon is reported to be 
induced optimally at a dissolved O2 concentration of 0.7% (Aung et al., 2014). However, 
it is unclear whether this induction is due to microaerophilia only as the ArcAB two 
component system and FNR systems in E. coli do not necessarily respond to O2 levels 
but may be indirectly sensing the redox poise of cell (Iuchi et al., 1990, Lynch, 1996). 
Based on amino acid homology, the M. smegmatis cydDC operon and its homologs in 
Mtb are predicted to encode subunits characteristic of the ATP Binding Cassette (ABC) 
domain, suggesting that they are ABC transporters (Black et al., 2014, Aung et al., 
2014). These proteins are discussed further below 
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1.10.3  ABC transporters 
ATP Binding Cassette (ABC) type transporters are ubiquitous in nature and constitute 
one of the largest of all protein families (Linton and Higgins, 1998). Members of this 
family couple energy of ATP hydrolysis to a wide variety of solute translocation across 
cellular membranes. ABC-type transporters share a common architectural organization 
comprising two hydrophilic ABC and two hydrophobic transmembrane domains 
(TMDs)(Szmelcman et al., 1976) (Figure 1.9). The hydrophilic ABC domain is 
characterized by the presence of a conserved ATP hydrolyzing domain of approximately 
215 amino acids called the ABC or nucleotide binding domain (NBD). The archetypal 
ABC domain has remarkable conservation of primary sequence of the cassette and is 
characterized by several short motifs, namely: the presence of the Walker A and Walker 
B motifs, which are indicative of the NBD and the signature motif, located upstream of 
the Walker B motif. Other motifs diagnostic of the ABC domain include the Q-loop, 
consisting of a conserved glutamine residue located upstream of the Walker A motif. 
Also, downstream of the Walker B motif is the H-loop consisting of a conserved 
Histidine residue (Szmelcman et al., 1976). The organization of this domain is also 
remarkably conserved across many ABC transporters.  
The TMDs preserve the substrate translocation passageway. Unlike the NBD of 
different ABC transporters, the translocation pathway exhibits extreme variability in 
conservation (Hiles et al., 1987). This enables ABC transporters to translocate a wide 
variety of substrates in and out of the cell membrane. Additionally, ABC transporters 
have a variety of physiological roles not limited only to transmembrane passage. For 
instance, ABC transporters are of high medical and economic relevance often 
implicated in antimicrobial resistance and chronic diseases such as cystic fibrosis 
(Gerlach et al., 1986, Gros et al., 1986).  
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ABC transporters belong to three main classes based on functional category. The first 
class comprise importers, which include all members that mediate the uptake of 
nutrients, Second, is the functional class of exporters, which refers to all members that 
secrete various molecules and the third functional category includes non-transport 
related functions such as translation of mRNA and DNA repair (Doolittle et al., 1986). 
 
1.10.4  Functional mechanism of ABC-type transporters 
Crystallization of certain ABC members has allowed elucidation of the functional 
mechanistics associated with ABC proteins. All ABC transporters contain the larger 
A B C
D E F
Figure 1.9. Schematic illustration of gene fusion events culminating in multidomain
proteins which is a prominent feature of ABC transporters. The archetypal ABC
transporter contains four domains. The two transmembrane domains (TMD) can be
hetero-or homodimeric domains (Shaded squares). Similarly, the 2 ATP Binding
Cassette domains (Ovals) (ABCs) can be encoded as hetero- or homodimeric subunits.
The domains can exist in various associations: A) Four separate domains B) Fused
ABC domains with heterodimeric TMDs C) Fused TDMs with homodimeric ABC
domains D) One TDM fused to one ABC domain (as in CydDC), E) One TDM fused to
one ABC but also including separate TDMs and ABCs and F) All four domains in a
single protein. Adapted from Linton and Higgins 2001.
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transmembrane domain and the smaller ABC helical domain, with 3-4 helices (Linton 
and Higgins, 1998). The two domains are connected by two flexible loops such as the 
Q-loop, which mediates the connection between TMDs and ABC domains (Hollenstein 
et al., 2007, Dawson and Locher, 2006). For transport to occur, irrespective of whether 
the protein is an importer or an exporter, oligomerization of the polypeptides must first 
occur. It has been established that during transport, the Walker A motif of one subunit 
interacts with the Walker B of the other subunit. ATP is required for dimerization. This 
was shown by mutagenesis of essential residues in the protein crystal or by employing 
EDTA to prevent ATP hydrolysis in the co-purification of the dimer (Hollenstein et al., 
2007). In both cases, 2 molecules of ATP were observed in association with the dimer 
interface. More specifically, one ATP molecule interacts with the Walker A motif of one 
subunit, and another molecule with the signature motif of the other subunit (Hollenstein 
et al., 2007). ATP hydrolysis requires stabilization of the adenosine group in ATP. The 
adenosine group is stabilized by a group of conserved aromatic residues preceding the 
Walker A motif. A conserved lysine residue within the Walker A motif forms a hydrogen 
bond with the oxygen atoms of the adenosine group and the two phosphates thus 
spatially orientating both phosphates (Geourjon et al., 2001). A conserved histidine of 
the H-loop is also necessary for ATP hydrolysis and plays a major role in the 
stabilization of the adenosine ring by forming a hydrogen bond with the last phosphate 
group (Geourjon et al., 2001). 
For transportation of nutrients into the cell, the periplasmic binding protein releases the 
substrate into the TMDs which are capable of binding and transporting 2 substrates 
concurrently. Substrate binding induces conformational changes in the TMDs that relay 
signals to the ABC domains for ATP hydrolysis-facilitated translocation (Senior et al., 
1995). For exporters such as the CydDC, once the substrate binding occurs, the re-
orientation of the substrate binding site on the inside of the membrane, with the 
concomitant reduction in its affinity for the substrate, must first occur. This 
conformational change culminates in ATP hydrolysis and substrate extrusion into the 
periplasm (Senior et al., 1995). 
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1.10.5  The role of CbdO in E.coli 
E. coli respires using two membrane-bound terminal oxidases under aerobic conditions 
namely: cytochromes bo and CbdO (Kita et al., 1984, Anraku and Gennis, 1987). The 
cydAB operon encoding CbdO is expressed both aerobically and anaerobically (Cotter 
et al., 1990, Poole and Cook, 2000). Consistent with this, the expression of CbdO is 
remarkably high under hypoxia, with the enzyme having extraordinary affinity for O2 
(D'mello et al., 1996). Loss of CbdO results in complex phenotypic defects. Phenotypic 
consequences of loss of CbdO in E. coli includes the inability to exit stationary phase at 
high temperatures under aerobic conditions (Siegele et al., 1996); sensitivity to high 
temperature (Delaney et al., 1992), hypersensitivity to H2O2 (Delaney et al., 1992); 
sensitivity to several metal ions (Cook et al., 1998, Poole et al., 1989); loss of motility 
and increased benzylpenicillin sensitivity (Pittman et al., 2002).  
In E. coli, the cydD and cydC genes are transcribed as a separate operon from the 
cydAB, and are necessary for CbdO assembly (Georgiou et al., 1987, Poole et al., 
1989, Poole et al., 1993, Delaney et al., 1993, Bebbington and Williams, 1993, Aung et 
al., 2014). These genes encode heterodimeric components of the ABC domain similar 
to those of ABC transporters (Poole et al., 1993) as shown in Figure 1.8 and Figure 1.9. 
E. coli encodes approximately 80 ABC transporters (Linton and Higgins, 1998). It was 
proposed that the substrate of the CydDC might be heme (Poole et al., 1993, Poole et 
al., 1994). However, Goldman and coworkers later proved that the export of heme to the 
periplasm and its assembly into heterodimeric apoproteins does not require cydC 
(Goldman et al., 1996b). More importantly, transport studies using everted membrane 
vesicles revealed no significant differences between wild-type and cydD mutant strains 
(Cook and Poole, 2000). Intriguingly though, overexpression of CydDC results in the 
synthesis of a novel heme pigment in anaerobically grown cells, suggesting a link with 
heme metabolism (Cook et al., 2002).  
A quantum leap in understanding the functioning of CydDC was the observation that the 
periplasm of a cydC mutant is more oxidizing than that of wild-type (Goldman et al., 
1996b). This, and the observation that CydC deficiency can be corrected by exogenous 
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reducing agents, suggested that CydDC exports a reducing molecule to the periplasm 
for maintenance of redox homeostasis (Goldman et al., 1996a, Pittman et al., 2002). It 
was further demonstrated that CydDC exports reduced GSH and cysteine to the 
periplasm in an ATP-dependent manner (Pittman et al., 2005, Pittman et al., 2002). The 
sensitivity of a cydD mutant to benzylpenicillin and dithiothreitol, and the loss of motility, 
were all reversed by addition exogenous (Pittman et al., 2002) cysteine. The addition of 
cysteine also increased cytochrome c levels in the periplasm of a cydD mutant, 
however, did not correct the biogenesis (Poole et al., 1994) defect. Consistent with the 
CydDC being a cysteine exporter, a cydD mutant displayed hypersensitivity to high 
cysteine concentrations in the medium and accumulated higher cytoplasmic cysteine 
levels. CydDC overexpression confers resistance to high extracellular cysteine 
concentrations.  
1.10.7  CbdO in pathogenesis 
The presence of CbdO in pathogenic bacteria is associated with virulence in humans 
and livestock. For instance, all members of the Mtb complex, which includes genetically 
related pathogens associated with TB pathology, possess CbdO (Kana et al., 2009). 
Furthermore, in Shigella flexneri and Brucella abortus, the loss of CbdO resulted in 
attenuation of intracellular survival and virulence (Way et al., 1999, Endley et al., 2001). 
Therefore, the need to understand CbdO assembly is critical to developing drugs that 
will target this respiratory complex.  
1.10.6  F1F0 ATP synthase 
ATP is the biological currency of every living cell. Cells obtain energy through various 
metabolic pathways including substrate level phosphorylation, a process that does not 
depend on the reducing potential of external electron donors for ATP synthesis (black et 
al., 2014). On the contrary, microorganisms that depend on the presence of oxygen for 
growth, produce the bulk of their ATP through oxidative phosphorylation (OxPhos). The 
ATP synthase is a highly conserved and widely distributed energy generating enzyme in 
both prokaryotes and eukaryotic mitochondria (Elston et al., 1998). During the terminal 
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step of OxPhos, the membrane bound F1F0 ATP synthase dissipates the free energy of 
the electrochemical gradient to synthesize ATP through the phosphorylation of ADP 
(Weber and Senior, 2003). The F1F0 ATP synthase is an extremely small rotary engine 
which is composed of the peripherally located, aqueous soluble F1 rotary motor and the 
membrane confined F0 rotary motor (Weber and senior 2003, black et al 2014 and 
dimroth et al 200). The F1 motor is encoded by the α3β3γδε subunits while the F0 
segment is encoded by ab2Cn(10-15) (Weber and Senior, 2003, Black et al., 2014). 
Collectively, the γεCn unit is called the central or rotor stalk while b2 and δ is called the 
stator stalk which prevents rotation of both the F1 and F0 motors. Rotation of the central 
stalk relative to the hexagonic F1 motor induces torque in the F0 motor, which allows 
proton translocation through the C-rings which engages the three functional catalytic 
sites on the F1 segment for ATP synthesis (Figure 1.10).  
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Figure 1.10. Schematic representation of the F1F0 ATP synthase. The ATP synthase has ATPase activity
as well. The ATP synthase is composed of the membrane bound F0 region and the hydrophillic F1 region.
ATP is synthesized by utilizing the free energy of the proton gradient. Adapted from Kana et al., 2009.
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Conversely, evidence of ATP hydrolysis mediated torque of the three functional catalytic 
sites on the F1 rotor, induces proton translocation across the cytoplasm (Weber and 
Senior, 2003). The ATP synthase forms an essential component for synthesis of 
metabolic energy in Mtb (Berney and Cook, 2010, Black et al., 2014). This enzyme 
complex is conserved across the mycobacteria and is encoded by the atpBEFHAGDC 
operon and functions essentially the same as described above during aerobic 
conditions. Furthermore, during hypoxic growth, another enzyme that mimics the 
functioning of the ATP synthase called the methylmalonyl-CoA decarboxylase, 
generates ATP through dissipating the Na+ gradient generated by fermentation of 
succinate (Becher and Müller, 1994). However, this has not been demonstrated in any 
species of the mycobacteria.  
1.11 Rationale for this study 
During TB pathogenesis, Mtb is engulfed by alveolar macrophages which eventually are 
surrounded by other immune cells to form a barrier of containment. This barrier also 
provides a protective niche for Mtb to survive indefinitely under immune pressure. In 
such a granulomatous environment, Mtb is subjected to suboptimal hypoxic conditions 
were its active growth is kept in check by the immune response. We hypothesize that 
under these conditions, the biological role for CbdO switches from being supportive to 
critically essential for survival. It is expected that during hypoxic growth, the levels of 
expression of CbdO is elevated and this contributes towards pathogenesis as 
demonstrated previously (Way et al., 1999, Endley et al., 2001) in B. abortus and S. 
flexinerri. Furthermore, it has been established in various model and pathogenic 
microorganisms that during hypoxic persistence and stationary growth phase, CbdO 
provides for energetic requirements and protects from various environmental stresses 
while electron flux through the main aerobic branch is reduced by low oxygen tension. 
To further explore CbdO biology, this MSc will focus on the cydDC-encoded ABC 
transporter.  
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1.10.9  Hypothesis 
It is our hypothesis that the cydDC operon encodes a heterodimeric ABC type 
transporter, whose substrate is a thiol containing compound (reduced glutathione) which 
maintains a balanced redox poise in the periplasm and thus contributing to the 
biogenesis and functioning of CbdO in Mtb. Hence, in the absence of CydDC, we 
expect that CbdO will not assemble properly and the spectroscopic features of this 
respiratory enzyme will be missing from membrane preparations of M. smegmatis.  
1.10.10  Aim 
To investigate the function of the cydDC encoded ABC type transporter in M. 
smegmatis. 
1.10.11  Objectives 
 The sequenced genome of M. smegmatis suggests that the cydC gene contains 
a SNP that would render it non-functional. We propose that this is a sequencing 
mistake, as the spectroscopic features of CbdO are present in wild type M. 
smegmatis (Kana et al., 2001) , suggesting that this organism has a functional 
cydDC operon. We will prove this by sequencing the cydC locus. 
 Prove the functionality of the M. smegmatis cydDC genes by heterologous 
expression in an E. coli cydD mutant. 
 To construct a suicide vector for the deletion of the cydDC operon in M 
smegmatis.  
 To use this above mentioned suicide vector for allelic exchange mutagenesis in 
M. smegmatis.  
 To characterize the resulting mutant for CbdO assembly by assessing membrane 
fractions for spectral features associated with CbdO.  
 To phenotypically assess the mutant strains under various stress conditions 
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2.  Materials and Methods 
2.1 Bioinformatic tools and virtual software programs 
Several in silico tools were used to view, analyze, design, compare, edit and manipulate 
bacterial gene sequences of interest and their homologs. These are outlined below.  
2.1.1 Databases used in this study 
Table 2. Database and their application in this study 
Name Website address Application 
 
Smegmalist 
 
 
 
 
http://mycobrowser.epfl.ch
/smegmalist.html 
 
Nucleotide or protein 
sequences of specific 
genes were downloaded 
from Smegmalist. 
 
EcoCyc http://www.ecocyc.org/EC
OLI/organism-summary 
Sequences of E. coli were 
obtained from this website. 
 
Tuberculist http://tuberculist.epfl.ch Sequences of interest 
(nucleotide or protein) of 
Mtb were obtained from 
Tuberculist. 
 
2.1.2  NCBI BLAST (http://blast.ncbi.nlm.nih.gov/Blast.cgi) 
The Basic Local Alignment Sequence Tool was used to identify sequences of 
proteobacterial and actinobacterial microorganisms encoding the cydDC type ABC 
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transporter homologs. This online tool is also a comparative genomics tool that allows 
the alignment of nucleotide or amino acid sequences. This tool was used to align 
sequences of Mtb, M. smegmatis, E. coli and various other microorganisms. 
2.1.3 Clustal Omega or Clustal W2 (http://www.ebi.ac.uk/Tools/msa/clustalo/) 
Clustal Omega suite was utilized to align multiple sequences in high throughput or in 
pairs, in an attempt to identify regions of homology of the ATP binding cassette of 
different microorganisms. Both of the clustal suites were used.  
2.1.4 I-TASSER (http://zhanglab.ccmb.med.umich.edu/I-TASSER/) 
As the crystal structure of the cydDC is yet to be determined, a protein threading tool 
(Iterative Threading ASSEmbly Refinement server) was used to predict the structure of 
the M. smegmatis cydD and cydC subunits. 
2.1.5 PyMOL (https://www.pymol.org/) 
Pymol allows for the visualization of Protein data bank files. The M. smegmatis cydD 
and cydC predicted structure was visualized and manipulated using this software. 
2.2 Chemicals and Reagents 
All chemicals, reagents and primers used in this study, except when stated, were 
procured from Sigma Aldrich and Inqaba biotech while enzymes and buffers were 
procured from Roche, Fermentas and New England Biolabs (NEB). For an in depth list, 
refer to Appendix A. 
2.3 Bacterial strains and cultivation conditions  
For plasmid propagation, the laboratory stock of E. coli DH5 , strain K12 and derivative 
strains were cultivated in selective broth: (Luria Bertani [LB]/ 2XTY) or selective Luria 
agar media (LA) supplemented appropriately with antibiotics at the following 
concentrations: 200 g/mL hygromycin (Hyg), 200 g/mL ampicillin (Amp), 50 g/mL 
kanamycin (Kan), 50 g/mL and streptomycin (Strp). Bacteria were propagated in broth 
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in a shake flask incubator overnight. Broth cultures with recombinant plasmids > 8 KB 
were propagated at 30 C (New Brunswick Scientific Innovar  4000) with shaking at 
100 rpm, while those carrying plasmids < 8 KB were grown at 37 C with shaking at 
100-250 rpm. Strains with plasmid sizes > 8 KB or <8 KB were propagated in solid 
media at 30 C and 37 C respectively. E. coli strains used and/or generated in this 
study are outlined below 
Table 2.1. List of plasmids and strains used and generated in this study 
 
Name Description Source 
Plasmids   
p2NIL Cloning vector; KmR Parish et al., 
2000 
pGOAL17 Plasmid carrying , lacZ, and sacB 
genes as a PacI cassette; 
Parish et al., 
2000 
pBlueScript E. coli cloning vector; amp
R; lacZ-
alpha; oriE 
Promega 
pSE_100 E. coli-Mycobacterium shuttle vector 
carrying Pmyc1tetO; HygR 
(Ehrt et al., 
2005) 
pMAS Derivative of pBlueScript. Plasmid 
carries the aadA cassette encoding, 
StrpR  
CBTBR 
pMV306H pMV306 derivative carrying HygR 
marker L5 integrating proficient E. 
coli–Mycobacterium shuttle vector 
integrating at tRNAGly ; HygR. 
H. Boshoff 
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pOTBcyd Plasmid carrying the whole Mtb cyd 
operon; HygR 
Kana et al., 
2001 
pGEM29M Plasmid carrying M. smegmatis cyd 
operon 
Kana et al., 
2001 
pBlueScriptΔcydDC Plasmid carrying 1176 bp upstream 
sequence including 24 bp sequence 
of cydD to create an inframe deletion 
and 864 bp of downstream sequence 
of cydC, including 36 bp of cydC 
sequence to generate an inframe 
double deletion allele of the cydDC 
AmpR 
This study 
p2NILΔcydDC Suicide plasmid carrying a cydDC 
truncation excised from 
pBlueScript∆cydDC as 2007 bp 
HindIII fragment, KanR 
This study 
pSE:pOTBcyd Episomal overexpression construct, 
carrying the whole Mtb cyd operon. 
HygR 
This study 
pTweety::cydDC 
 
Cloning of the cydDC operon in a 
shuttle vector kanR 
 
This study 
 
pTweety Complementation vector carrying an 
integrase gene. KanR 
(Pham et al., 
2007) 
pNIT Mycobacterial replication plasmid that 
allows the inducible expression of the 
(Murphy et 
al., 2015) 
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phage Che9c RecET recombination 
system, and constitutive expression 
of the sacB gene. KanR 
Escherichia coli 
DH5α 
Host strain for cloning and sub 
cloning. supE44 ΔlacU169 hsdR17 
recA1 endA1 gyrA96 thi-1 relA1 
Hanahan 
(1983) 
Escherichia coli 
wildtype K12 (3561) 
Wildtype E. coli K12 strain Robert K 
Poole , 1993 
3562 K12 E. coli ΔcydD strain Robert K 
Poole , 1993 
ΔcydD(pSE:pOTBc
ydABDC) 
Overexpression construct 
transformed into E. coli cydD deficient 
strain 
This study 
mc2 155::∆cydDC_ 
pMVpcydDC 
Complementation of M. smegmatis 
cydDC  mutant strain using an 
integrating plasmid HygR 
This study 
M.  smegmatis  
mc2 155 
Electrocompetent High frequency 
transformation mutant of M. 
smegmatis  ATCC 607 strain  
Snapper et al. 
(1990) 
M. smegmatis:: 
pTweety pcydDC_ 
Complementation of M. smegmatis 
cydDC mutant strain using an 
integrating shuttle vector. KanR 
This study 
M. smegmatis 
∆cydDC 
M. smegmatis with an inframe double 
deletion allele of the cydDC operon. 
This study 
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M. smegmatis mc2 155 and its derivative strains, were cultivated either in Middlebrook 
7H9 broth media (Difco), supplemented with 0.2% glycerol, 0.05% tween 80, 0.085% 
NaCl, 0.2% glucose and 0.5 % glycerol (referred to as 7H9 media) and 7H10 solid 
media supplemented with 0.085% NaCl, 0.2% glucose and 0.5 % glycerol (referred to 
as 7H10 media) with and without shaking respectively. Where necessary, derivatives of 
M. smegmatis mc2 155 were cultured in selective media with antibiotics at the 
concentration of 25 g/mL Kan or Strp or 50 g/mL Hyg. 
For growth under defined oxygen tensions, M. smegmatis was cultivated in a bioreactor 
as described by (Kana et al., 2001). Briefly, batch cultures of M. smegmatis mc2 155 
and its derivative strains, were carried out in a New Brunswick BioFlow fermentor 110. 
The 2L bioreactor vessel had a 1L working volume and the following mechanical 
features:  
 Two, six bladed axial flow impellers mounted on a stirring shaft that was 
controlled by an over-head rotor, connected to the control box for electronic 
speed adjustment.  
 The reactor was equipped with a temperature blanket with a water cooling coil 
circuit system and a temperature probe to monitor and maintain a heat stable 
environment 
 A pH probe to monitor and adjust changes in pH 
 A Mettler Toledo dissolved oxygen probe dipped inside the cultivation media to 
detect fluctuations in dissolved oxygen. Oxygen was supplied by passing 
compressed air through the ring sparger by means of an external, manually 
controlled rotometer which had a capacity between 0-400 mL/min of air supply.  
 The unit also had a foam probe and a sampling port.  
The electric heat blanket and all probes were linked to the control unit which kept tight 
regulation of the selected variables within set limits when the cruise/cascade mode was 
selected. Agitation ranged between 50-650 rpm and was set to cascade mode in order 
to control air saturation, which allowed the unit to modulate impeller speed for 
maintaining the set point dissolved oxygen. For growth of M. smegmatis cultures, the 
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vessel was sterilized with 1L 7H9 containing 3 mL glycerol. Upon cooling, 7H9 was 
supplemented with 2 mL 25% tween 80, 0.6 mL antifoam and 10 mL 100X glucose/salt 
mix (0.085% NaCl and 0.2% glucose). The vessel was equilibrated overnight and the 
dO2 probe calibrated to 0% air, by sparging the media with compressed nitrogen, then 
to 100% by introducing compressed air. A stationary phase pre-culture (100 mL) was 
inoculated into the vessel and the cultures cultivated at 21, 10, 5, 1, and 0.7% dO2 in 
cascade mode. At 21 and 0.7% dO2 tension, a sample was withdrawn through a 
vacuumed sampling port. Cells were harvested through centrifugation. 
2.4  DNA manipulation 
2.4.1 Small scale plasmid preparation (Alkaline lysis) 
Plasmid extraction was carried out as described by (Sambrook et al., 1989). A single 
colony was inoculated in a culture flask containing 2 mL LB supplemented appropriately 
with antibiotics. 1 mL freezer stock of the pre-culture was prepared and cryogenically 
preserved at -80 C, the remainder was precipitated at 16162 x g for 1 min and the 
pellet was re-suspended in 100 L ice cold solution I (50 mM glucose, 25 mM Tris-HCl 
[pH 8.0] and 10 mM EDTA). Subsequently, 200 L of room temperature solution II 
(1%SDS and 0.2 M NaOH) was added, and the suspension thoroughly mixed by gentle 
inversion (6-8 times). The suspension was incubated at room temperature for 
approximately 5 min, followed by the addition of 150 L ice cold solution III (3 M 
potassium acetate and 11.5% acetic acid). The suspension was mixed and incubated 
on ice for 5 min. Thereafter, centrifugation at 16162 x g for 10 min at room temperature 
was carried out and the clarified supernatant decanted into a sterile 1.5 eppendorf tube 
containing 5 L RNAse A (10 mg/mL), followed by incubation at 42 C for 15 min. 
Isopropanol (600 L) was added to the suspension and the DNA was collected by 
centrifugation at 12470 x g for 20 min. The supernatant was discarded and the 
transluscent pellet was washed twice with 500 L of 70% ethanol at 12470 xg for 5 min 
and dried in an Eppendorf concentrator at 60 C for 12 min. The pellet was re-
suspended in 30 L of nuclease free water by incubating the tubes at 37 C for 15 min, 
` 
40 
 
gently flicking the side of the tubes and centrifuging for 10 sec at maximum speed in a 
microfuge. 
2.4.2  Sodium acetate precipitation 
To remove excess salts that might interfere with the activity of restriction enzymes, 
plasmid extracts were purified as follows: one tenth 3M sodium acetate (pH 5.3) of the 
total volume and 3X the total volume of 100 % ethanol were added to the DNA. The 
sample was mixed and incubated at -20 C for 15 min. Subsequently, centrifugation at 
12470 x g for 20 min at ambient temperature was carried out and the translucent pellet 
was washed, dried and re-suspended as previously described (see 2.4.1)  
2.4.3  Bulk preparation of plasmid DNA 
For bulk preparation of DNA, the small-scale protocol (described in section 2.4.1) was 
scaled-up. Bulk extraction of plasmid DNA was carried out from 50 mL of overnight 
culture and the volumes of all solutions were increased ten-fold. For sequencing and 
electroporation purposes, the Nagel-Macherey nucleobond kit was used for plasmid 
bulk preparation, following the manufacturer‘s specifications. Briefly, an overnight 
culture (50 mL) was precipitated by centrifugation at 3901 x g for 10 min. The pelleted 
cell mass was thoroughly re-suspended in 4 mL cold buffer S1 (50 mM Tris-HCl, 10 mM 
EDTA, 100 µg/mL RNAse pH 8.0) by vortexing. After the addition of 4 mL room 
temperature buffer S2 (200 mM NaOH, 1% SDS), the suspension was incubated at 
ambient temperature for approximately 5 min, followed by the subsequent addition of 4 
mL cold buffer S3 (2.8M potassium acetate pH 5.1), and incubation on ice for a further 5 
min. To clarify the cell lysate, the suspension was centrifuged at 3901 x g for 20 min 
and the supernatant transferred to a column with a silica membrane, equilibrated with 
2.5 mL buffer N2 (100mM Tris, 15% ethanol, 900mM KCl, 0.15% triton X-100 pH 
adjusted to 6.3 with H3PO4). This was accompanied by two wash steps with 10 mL 
Buffer N3 (100mM Tris, 15% ethanol, 1.15 M KCl and pH adjusted to 6.3 with H3PO4). 
Solution N5 (5 mL) (100mM Tris,15% ethanol, 1. M KCl and pH adjusted to 8.5 with 
H3PO4) was used to elute the DNA into a 50 mL conical tube, containing 4 mL room 
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temperature isopropanol. One mL aliquots of this suspension were immediately 
centrifuged at 12470 x g for 20 min in 1.5 eppendorf tubes. The pellet was washed and 
dried as previously described (2.4.1), re-suspended in elution buffer (15 L) and pooled 
into one tube. 
2.4.4  Mycobacterial genomic DNA extraction 
DNA from M. smegmatis and its derivative strains was isolated following the modified 
Cetyl trimethyl ammoniumbromide (CTAB) DNA extraction protocol described by 
(Somerville et al., 2005). Mycobacterial cultures were propagated in 7H9 broth to an 
optical density of (OD600) of 2. A 1 mL freezer stock of this culture was prepared and 
cryogenically preserved at -80 C. Bacterial culture (2 mL) was precipitated by 
centrifugation at 16162 x g for 2 min. The cell pellet was re-suspended in 500 L of 
0.01M TE buffer (pH 8.0) and incubated at 65 C for 20 min. Thereafter, 70 L of 
lysozyme (10 mg/mL) was added to the heat killed suspension, thoroughly mixed by 
gentle inversion and incubated at 37 C for 60 min. Following the addition of 6 L 
proteinase K and 70 L 10% SDS, the suspension was mixed and incubated at 65 C for 
120 min after which, 100 L of 5M sodium chloride and 80 L pre-warmed CTAB/NaCl 
were added to the suspension, followed by incubation at 65 C for 10 min. Thereafter, 
750 L of chloroform/isoamyl [ratio of 24:1 (v/v)] was added and the suspension mixed 
vigorously by inversion. The suspension was centrifuged at 12470 x g for 10 min and 
800 L of the top aqueous layer transferred to a sterile 1.5 mL eppendorf tube 
containing 450 L chilled isopropanol. The suspension was centrifuged at 12470 x g for 
20 min and the pellet washed, dried and re-suspended as previously described (see 
2.4.1). 
2.4.5  Mycobacterial small-scale genomic DNA extraction 
For screening purposes, genomic DNA was isolated as follows: five hundred (500 L) of 
overnight culture was harvest by centrifugation at 16162 x g for 2 min (2.4.4) and re-
suspended in 100 L of distilled water. Chloroform (100 L) was added to the, and the 
suspension was mixed by inversion. The suspension was heat killed by incubation at 65 
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°C for 15 min, followed by centrifugation at 12470 x g for 15 min. The top aqueous layer 
containing DNA was transferred to a sterile labelled eppendorf tube and stored at 4 °C 
for later use. 
2.5  Nucleic acid quantitation 
Quantification of nucleic acids (DNA and RNA) is important in processes such as 
restriction digests, cloning and southern blot analysis. To measure the quantity of DNA 
in a sample, a property of light absorption by DNA is exploited. DNA absorbs light at a 
wavelength of 260 nm. Quantification of DNA or RNA was facilitated by the use of the 
Nanodrop ND-1000 spectrophotometer (Nanodrop Technologies) used in conjunction 
with software from the manufacturer (Coleman Technologies). Alternatively, a standard 
volume of DNA was visualized on a 1% agarose gel parallel to a molecular weight 
marker and the concentration of the DNA was inferred by comparing the intensity of the 
bands relative to Roche DNA ladder II. 
2.6  Polymerase chain reaction (PCR) 
Amplification of genomic DNA was facilitated by PCR. For this, primers homologous to 
the genomic region of interest were designed by the Clone Manager suite of programs. 
2.6.1  Gene knockout primers 
Genome editing was accomplished by the design of primers for gene knockout. Primers 
had the 21 bp of sequence homologous to regions upstream and downstream of the 
gene of interest, a GC clamp and restriction sites were incorporated to facilitate cloning. 
The primers were thus engineered to generate a truncated version of the original gene. 
Amplification of PCR amplicons for cloning was facilitated by a high fidelity DNA-
dependent DNA polymerase with proofreading activity. A gradient PCR (to determine 
the optimum annealing temperature for primers) was initially set up to a final volume of 
25 L according to the manufacturer‘s specification with the following components in the 
master mix: dNTPs were added to a final concentration of 0.2 mM, 5X recommended 
buffer was included in the reaction mixture, the forward and reverse primers were added 
to a final concentration of 1 M each, template DNA between 50-150 ng/ L, 1% DMSO, 
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2 units of DNA polymerase and the volume topped up to 25 L with sdH2O. Cycling 
conditions for amplification were typically as follows: 1 cycle of denaturation at 98 C for 
3 min; 1 cycle of denaturation at 98 C for 30 sec; 30 cycles of the following steps: 
annealing at 50-70 C for 1 min, extension at 72 C for 1 min; 1 cycle final extension at 
72 C for 10 min and 1 hold cycle at 12 C, overnight. 
For screening of potential mutants by PCR, a DNA polymerase with no 3`-5` 
exonuclease activity was employed. The PCR master mix was prepared according to 
the manufacturer‘s recommendations except that DMSO was replaced with 1 X GC 
buffer and 2 mM MgCl2 was used. With regards to the cycling conditions, 95 C of 
denaturation was used instead for 3 min. The rest of the cycling conditions are as stated 
above. 
2.6.2  Sequencing primers 
Overlapping primers (between 18-24 bp) for sequencing, were designed at least a 100 
bp upstream and downstream from the genomic region of interest for every 350 bp. In 
some instances, bidirectional sequencing was done with several reverse primers 
spanning the region of interest. See below for primers used for sequencing 
Table 2.2 cydC sequencing primers 
Primer name Sequence 5`-`3 Position  
cydC_Fwd ATGATCCGTTGCTCCGCCTGA Binds 100 bp 
upstream cydC 
cydC Int Fwd_ ACCTTCGAGCGTCATCACCGC Binds inside cydC 
cydC_Rvs CGGTACAGCGAACAAAATCGG Binds 100 bp 
downstream 
cydC 
` 
44 
 
2.6.3  Primers for creating suicide constructs and complementation vectors  
Primers to amplify the full length gene/s of interest were designed, and engineered as 
previously described (see 2.6.1). A high fidelity polymerase was used to generate the 
fragment according to the cycling conditions already described (see 2.6.1). Primers for 
creating gene knockouts are given in Table 2.4 and for sequencing the construct, 
primers are given in Table 2.5. Primers for genetic complementation are given in Table 
2.6. 
Table 2.3 Gene knock out primers 
Region 
targeted  
Primer 
name 
Sequence 5`-`3 Amplicon Position  
cydD 
upstream 
region 
cydD 
upstream 
Fwd 
cydD 
upstream 
Rvs 
GCGCGCAAGCTTGGCTTC
TTCCTGCTGGAG HindIII 
GCGCGCCAGCTGCGACG
ATGTGGGCGAGCA PvuII 
1176 bp From position 
1197 bp inside  
cydB to 21 bp into 
cydD 
cydC 
downstrea
m region 
cydC 
downstre
am Fwd 
cydC 
downstre
am Rvs 
GCGCGCCAGCTGCGGCC
GTCTCGCGGTG PvuII 
GCGCGCAAGCTTCGTCCG
CGACACGCCGGT HindIII 
864 bp From position 885 
downstream of 
cydC to 21 bp into 
cydC 
Restriction sites are underlined and the GC clamp is indicated in bold. 
Table 2.4 Suicide construct sequencing primers 
Sequencing primer Primer Sequence (5`-`3) amplicon 
Upstream Original GCGCGCAAGCTTGGCTTCTTCCTGCTG 420 bp 
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Forward 
Upstream new reverse 
GAG 
TCCCGCCACGGCGCTGGTAGC 
Upstream new forward 
Upstream original 
reverse 
TCCGTGCGCCACCTGTGTCCA 
GCGCGCCAGCTGCGACGATGTGGGCG
AGCA 
540 bp 
Downstream Original 
Reverse 
Downstream new forward 
GCGCGCAAGCTTCGTCCGCGACACGC
CGGT 
CGATGCCCAGCCCATTGCGCG 
460 bp 
Downstream new reverse 
Downstream original 
forward 
CGGGTCTGGTGCTGTGCTGGT 
GCGCGCCAGCTGCGGCCGTCTCGCGG
TG 
510 bp 
Restriction sites are underlined 
Table 2.5. Primers for genetic complemention 
Primer 
name 
Sequence 5`-`3 Position  Amplicon 
cyd 
comp 
Fwd 
GCGCGCAAGCTTTGAACCTCTGGCGTGCGC 
HindIII 
100 bp 
upstream of 
cydD 
 
 
3150 bp 
cyd 
comp 
Rvs 
GCGCGCCAGCTGACTCACCGGATCGGGTCG 
PvuII 
100 bp 
downstream 
of cydC 
Restriction sites are underlined 
For preliminary screen of the potential mutants and for complementation of the mc2 155 
∆cydDC::cydDC, the following primers were used. 
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Table 2.6 Mutant screening primers 
Primer name Sequence 5`-`3 Position  
US_Fwd TACCTGATCGCTGCGGTC Binds 52 bp upstream 
cydD 
DS_Rvs GTGTCTGACGACTCGGTCGAC Binds inside cydC 
cydC Int Fwd_ TTTCCGGTGGTCCTGCTCGAC Binds 168 bp 
downstream cydC 
2.6.4  Restriction digestion of DNA 
Restriction enzymes and buffers were procured from Fermentas, Roche or NEB. 
Restriction digests were carried out following the manufacturer‘s instructions. Restriction 
digests of PCR amplicons, plasmid DNA or genomic DNA were set up in a final volume 
of 10-30 L. An eppendorf tube containing sdH2O, 1X buffer, at least 1 g of (amplicon, 
plasmid) DNA and 1U enzyme (diluted in enzyme buffer to a ratio of 1:2) constituted the 
reaction mixture which was incubated at 37 C for 60 min. Buffers containing Bovine 
Serum Albumin (BSA) were utilized when a restriction enzyme had a dependency on 
BSA. For double digests, enzymes that were compatible in one buffer were preferred, if 
enzymes were not compatible in the same buffer, the enzyme that required a low ionic 
strength buffer took first preference, followed by digestion with an enzyme that required 
incubation in a high ionic strength buffer. When necessary, enzymes were heat 
inactivated at 65 C for 20 min. For southern blot analysis, at least 3 g of genomic DNA 
was digested in a final volume of 20 L with overnight incubation at 37 °C.  
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2.6.5  Dephosphorylation of DNA 
To reduce background due to re-ligation of vector during cloning, removal of phosphate 
groups in a linearized vector is necessary. For this, Antarctic phosphatase (NEB) was 
used (diluted in a ratio 1:2) to the buffer in the reaction mixture which contained 1X 
reaction buffer and was incubated at 37 C for 60 min, depending on the amount of 
DNA cut. The enzyme was heat inactivated at 65 C for 20 min. 
2.6.6  Phosphorylation of DNA 
For blunt end cloning, PCR amplicons were phosphorylated using polynucleotide kinase 
(PNK) (NEB) in 10-30 L reaction volumes containing the following constituents: dH2O, 
1X PNK buffer, 1 g DNA and 1U PNK. The buffer was always used in 1:10 ratios of the 
total volume while the enzyme/buffer ratio was always 1:2. The reaction was incubated 
at 37 C for 60 min.  
2.6.7  Modification of DNA overhangs 
Klenow (Thermofisher Scientific) was used to blunt overhangs generated during 
digestion of DNA with restriction endonucleases. The enzyme was used by following the 
manufacturer‘s instructions and retains the capacity to fill in overhangs in the 5` 
direction in the presence of dNTPs. The reaction was incubated at 37 C for 15 min and 
the enzyme was heat inactivated at 65 C for 20 min. 
2.6.8  DNA ligation 
Cloning involved ligation of either two or three DNA fragments. The T4 DNA ligase kit 
(NEB) was used according to the manufacturer‘s specifications for all cloning strategies. 
For this, a ligation reaction was set up in a final volume of 20 L with the following 
components, sdH2O, 1:10 enzyme buffer of the total volume, 1:1 volume ratios of the 
insert(s) and vector DNA and 1:2 enzyme to the buffer ratio (buffer component contains 
ATP). The reaction was incubated at room temperature overnight and was transformed 
into E. coli calcium chloride/ rubidium chloride competent cells. For the ligation reaction 
to be a success, optimum insert to vector concentrations are required. A standard 
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concentration of 50 ng/ L for the vector was always used. The amount of insert 
necessary for a 1:1 ratio of vector to insert was calculated as follows: 
 
 
 
2.7  Bacterial transformations 
2.7.1  E. coli transformations 
E. coli DH5  (1 mL freezer stock) was cultivated in 20 mL LB or 2XTY. A pre-culture (1 
mL) was inoculated in fresh 2XTY and incubated at 37 C with shaking at 250 rpm to 
OD600 of 0.5. Cells were cooled on ice for 15 min and harvested by centrifugation at 
3901 x g for 10 min at 4 C. Cells were re-suspended in 10 mL ice cold 0.1 M calcium 
chloride (CaCl2) and washed twice by centrifugation at 3901 x g for 10 min at 4 C in the 
same solution. Washed cells were re-suspended in 1 mL 0.1 M CaCl2 and incubated on 
ice for 30 min before use. For transformations, 100 L of competent cells were aliquoted 
into eppendorf tubes containing plasmid DNA (100-1000 ng/µL). The tubes were 
incubated on ice for 15 min. The suspension was heat shocked at 42 C for 90 sec for 
transformations and subsequently incubated on ice for 3 min. Cells were rescued in 800 
L 2XTY and incubated at 30 C or 37 C, depending on the size of the recombinant 
plasmid with shaking at 100 rpm. Transformants were plated on LA supplemented 
appropriately with antibiotic (see 2.3). Plates were dried in a biosafety cabinet level II 
(BSC II) and subsequently incubated as previously described (see 2.3) without shaking. 
Alternatively, chemically competent E. coli cells were prepared as previously described 
(Sambrook et al., 1989). Briefly, E. coli DH5  (1 mL freezer stock) was cultivated in 20 
mL LB or 2XTY at 37 C with shaking at 250 rpm to stationary phase. This pre-culture (1 
mL) was inoculated into fresh 2XTY (100 mL) and incubated at 37 C with shaking at 
250 rpm to OD600 = 0.5. Cells were cooled on ice for 15 min and harvested by 
Amount of insert= 50 ng (vector) * size of insert (bp) 
    size of vector (bp)  
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centrifugation (Beckman Coulter Allegra™ X-22R centrifuge) at 3901 x g for 10 min at 4 
C. The cell mass was re-suspended in 0.4 volumes TfbI (30 mM potassium acetate, 
100 mM rubidium chloride, 10 mM calcium chloride, 50 mM manganese chloride, 15 % 
v/v glycerol). After being chilled on ice for 12 min, cells were harvested as before and 
the cell pellet re-suspended in 0.04 original volumes of TfbII (10 mM MOPS, 75 mM, 10 
mM rubidium chloride, 15 % v/v glycerol). The solution was chilled on ice. Aliquots of 
this suspension (400 L) were used immediately. Alternatively, the cells were snap 
frozen in ethanol and stored at -80 C. For transformations, 100 L of competent cells 
were aliquoted into eppendorf tubes containing 100-1000 ng/µL plasmid DNA. Tubes 
were incubated on ice for 15 min. The cell suspension was heat shocked at 42 C for 90 
sec for transformations and subsequently incubated on ice for 3 min. Cells were 
rescued in 800 L 2XTY and incubated at 30 C or 37 C with shaking at 100 rpm. 
Transformants were plated on LA supplemented appropriately with antibiotic (see 2.3). 
Plates were dried in a BSC II and subsequently incubated at 30 C or 37 C without 
shaking. For recipes of all solutions, refer to Appendix A 
2.7.2  Mycobacterial electroporations 
For electroporations, 100 mL of M. smegmatis mc2 155 was propagated in a shake flask 
at 37 C as previously described (see 2.3) to OD600 = 0.8-1. Cells were harvested by 
centrifugation (Beckman Coulter Allegra™ X-22R centrifuge) at 3901 x g for 10 min at 4 
C. The pellet was re-suspended in ice cold 10% glycerol (v/v). The washing procedure 
was repeated twice and cells re-suspended in a final volume of 1 mL 10% glycerol (v/v) 
and used immediately. At least 1 g of plasmid DNA was mixed with 300 L competent 
cells in a 0.2 cm electroporation cuvette kept on ice. The BioRad Gene Pulser XCell™ 
system was employed for electroporations with the following settings: 2500 V, 25 F, 
1000 Ω and 0.2 cm. Cells were immediately rescued with 800 L 2XTY. For generation 
of knock out mutants via the recombineering strategy, rescue media was supplemented 
with isovaleronitrile (1 L for every 1 mL of media). Following overnight phenotypic 
expression of marker genes, the transformants were harvested, re-suspended in fresh 
media and subsequently propagated for 3-7 days as previously described (see 2.3) 
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2.8  Agarose electrophoresis 
Following plasmid extraction, PCR amplification, restriction profiling, genomic DNA 
digestion and cloning, separation of fragments on agarose gel was routinely done by 
agarose gel electrophoresis and visualized under UV. The principle of agarose 
electrophoresis is based on separation of DNA according to size. Agarose dissolved in 
45 mL 1X TAE buffer (40 mM Tris-acetate and 1 mM EDTA) and supplemented with 1.5 
L ethidium bromide (0.5 g/mL) was left to solidify with an 8 or 16 well comb in the 
casting tray, before being immersed in an electrophoretic tank containing 1X TAE. 
Samples were mixed with 3 L loading dye (containing glycerol and bromophenol blue) 
and were loaded alongside a molecular weight marker and separated at 80-100 V for 50 
min. DNA was visualized under UV and images saved using a GBox SynGene 
hardware operated by SynGene software (v7.1.2). A low percentage agarose gel (0.8-
1%) was prepared for the separation of high molecular weight DNA fragments. 
2.9  DNA purification 
DNA fragments of interest were excised from agarose gel for downstream processes 
such as cloning. The Nucleospin DNA extraction and purification kit (Macherey and 
Nagel) was employed for all gel purification purposes following the manufacturer‘s 
instructions. The DNA fragments of interest were first visualized as previously described 
(see 2.8) and the bands were excised using a heat sterilized scalpel. Appropriate 
protective gear was adorned while excising fragments on the illuminated bench top 
panel of the transilluminator in the dark room. Excised fragments were transferred to a 
sterile eppendorf tube and subsequently weighed on a bench top scale. For every 100 
mg of gel, 200 L buffer NTI was added and the tubes were incubated at 50 C for 10 
min. Once the gel was completely dissolved, the suspension was transferred to a 
column and centrifuged at 11000 x g for 30 sec. Following binding of DNA to the 
column, the flow through in the collection tube was discarded and the column washed 
twice at 11000 x g for 30 sec in 700 L buffer NT3. The membrane on the column was 
dried by centrifugation at 11000 x g for 60 sec. Buffer NE (30 L) was added to the 
columns fitted with sterile eppendorf tubes and incubated at ambient temperature for 5 
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min. DNA was eluted by centrifugation at 11000 x g for 60 sec and visualized as 
previously described (see 2.8). 
2.10  Sequencing 
All constructs generated via amplification of genomic regions of interest by PCR were 
sequenced. Sequencing primers (see 2.6.2) were designed and aliquots of constructs 
shipped to the Central Analytical Facility at the University of Stellenbosch. All 
sequences were analyzed with Seqman™or clustal suite of programs. For In silico tools 
used in this study, refer to section 2.1 
2.11  Preparation of freezer stocks, seed stocks and preservation of plasmids 
and strains 
At least 3 freezer stocks (0.5 mL) of each cloning vector, final knockout construct and 
strain were prepared in sterile 66% glycerol and cryogenically preserved at -80 °C for 
reference purposes. Similarly, 1 mL of cultures with the plasmids of interest were 
aliquated into several eppendorf tubes and were cryogenically preserved as previous. 
These were used as seed stocks to use in experiments. 
2.12  Construction of the cydDCKO constructs (Homologous recombination) 
Primers to generate a knockout construct of the cydDC operon were designed as 
previously described in Table 2.4 (see 2.6.1). A set of primers were designed to amplify 
1176 bp upstream of cydD. A GC clamp and HindIII site was engineered in the forward 
primer of the upstream region of cydD while a GC clamp and a PvuII restriction site was 
engineered into the reverse primer of the upstream region. Similarly, primers to amplify 
854 bp downstream of cydC were designed and had a HindIII restriction site in the 
forward primer, with a GC clamp and a PvuII restriction site engineered in the reverse 
primer, See Figure 2.1 below. 
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Primers were procured from Inqaba biotech. Amplification of both the upstream and the 
downstream regions was done by PCR as previously described (see 2.6.1). The 
amplicons were separated and visualized on a 1% agarose gel by electrophoresis at 80 
V for 50 min. To ensure the right fragment was amplified, a restriction enzyme that cut 
both the upstream and downstream regions asymmetrically was used for verification. 
The digests were separated by gel electrophoresis on a 1% agarose gel for 50 min and 
visualized under UV and images saved using a GBox SynGene hardware operated by 
SynGene software (v7.1.2). Both the upstream and the downstream amplicons were 
digested as previously mentioned (see 2.6.4) in a sequential digest of HindIII and PvuII. 
The HindIII enzyme was heat inactivated at 65 °C for 20 min. The cloning vector (p2NIL) 
was also digested with HindIII and the enzyme heat inactivated after one hour of 
Figure 2.1. Diagrammatic illustration of the construction of the cydDC suicide construct for use in homologous recombination. Both the
upstream and down stream of the operonic cydDC were PCR amplified and cloned into pBlueScript via the three way cloning strategy. The
fragment was purified as a HindIII fragment and a two way cloning stategy into p2NIL was carried out. Selectable marker genes were
cloned from pGOAL 17 into the suicide construct which was used to knock out the the cydDC in M. smegmatis.
M. Smegmatis
Chromosome
pBlueScript
p2NIL
DS
US
Kanamycin
lacZ
sacB
Final knockout 
construct
a) PCR amplify the upstream(US) and
downstream (DS) fragments of the
operonic cydDC.
b) Clone US and DS regions into pBlueScript
c) Purify HindIII fragment of US and DS
region and clone into p2NIL.
d) Clone PacI cassette from pGOAL17 into
Suicide construct
DSUS
864 bp1176 bp
Ampicilin
Kanamycin
DSUS
HindIIIHindIII
PvuII
HindIIIHindIII
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digestion at 37 C. The p2NIL was dephosphorylated as previously described (see 
2.6.5) and all fragments separated by gel electrophoresis. The fragments were gel 
purified as previously described (see 2.9). A ligation reaction was prepared as 
previously described (see 2.6.8) and the potential recombinants transformed as 
previously mentioned (see 2.7.1). Recombinant plasmids were extracted as previously 
described and verified by restriction profiling as previously mentioned (see 2.6.4). The 
suicide construct was sequenced as previously mentioned (see 2.10) and plasmid 
containing selectable marker genes digested with PacI and cloned. The final construct 
was transformed into the surrogate strain as previously described (see 2.7.1) and 
propagated at 30 C for 48 hours. Blue colonies that emerged were inoculated in broth 
and the plasmid subsequently extracted for profiling. Freezer stocks of this construct 
were prepared as previously mentioned (see 2.11). This construct was electroporated 
into M. smegmatis mc2 155. 
2.13  Construction of the cydDCKO constructs (Recombination genetic 
engineering - recombineering) 
A substrate for the deletion of the cydDC operon was designed using the clone 
manager suite of programs and synthesized by GeneScript. The linear substrate 
contained the following genetic elements: Upstream sequence of cydD (350 bp) flanked 
by a PacI site in the upstream position, a HpaI restriction site flanked by a 34 bp LoxP 
sequence separated from another 34 bp LoxP sequence by an EcoRV restriction site 
(Figure 2.2). At the terminal end of the second LoxP sequence, a HpaI restriction site 
was inserted, flanked by a downstream sequence of 350 bp) with a PacI site 
incorporated at the downstream terminal end. The linear substrate was synthesized by 
GeneScript and cloned into pUC57, encoding ampicillin resistance. Plasmid DNA (2 L) 
was transformed into the surrogate DH5  strain and the plasmid verified by restriction 
profiling as previously described (see 2.6.4). The plasmid (3404 bp) was linearized with 
EcoRV. A plasmid (pMAS 4306 bp) harbouring the 1.4 kbp Strp marker cassette was 
extracted, profiled using restriction enzymes and digested with EcoRV to release the 1.4 
kbp Strp cassette, which was subsequently gel purified (see 2.9). The linearized vector 
was dephosphorylated using NEB Antarctic phosphatase as previously described (see 
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2.6.5) and the 1.4 kbp Strp cassette was phosphorylated with NEB PNK for blunt end 
cloning as previously described (see 2.6.6). Both the insert and the vector were 
separated and visualized on a 1% agarose gel (see 2.8) and gel purified (see 2.9).  
 
The gel purified fragments were visualized once more before cloning to confirm integrity 
and concentration. A ligation reaction using NEB ligase was performed overnight as 
previously described (see 2.6.8). The ligation mixture was transformed into 100 L of 
CaCl2 competent cells as previously described (see 2.7.1) and selected on LA, 
supplemented with Strp for growth at 37 C. Recombinant plasmids were extracted and 
screened as previously described ( see 2.4.1 and 2.6.4)  
 
US
300 bp
PacI
DS
300 bp
PacI
LoxPLoxP
HpaI HpaIEcoRv
2.Order this vector
pUC57_simple
US
300 bp
PacI
DS
300 bp
PacI
LoxPLoxP
HpaI HpaIEcoRv
Amp
pUC57_simple
Amp
Strep 
Cassette
cydDCKO:Strp
Amp
US
300 bp
PacI
LoxP
HpaI
DS
300 bp
PacI
LoxP
HpaI
Strep
4.PCR amplify PacI fragment
5.Electroporate amplicon
6.PCR screen
1.Design substrate
3.Clone 
cassette
Figure 2.2. Diagrammatic illustration of the design of the recombineering substrate. Three hundred base pairs (300 bp) was
selected upstream of cydD and downstream of cydC with PacI restriction sites engineered in the upstream of cydD and
downstream of cydC. A blunt cutter (HpaI) was engineered immediately downstream and upstream of cydD and cydC
respectively to enable the removal of the LoxP-LoxP sequence which was separated by another blunt cutter (EcoRv). Following
cloning of the selectable marker cassette, primers specific for the substrate were used to amplify the substrate which was later
electroporated in M. smegmatis mc2 155 for allelic exchange by recombineering. Electroporations were plated in 7H10 strep and
incubated until colonies emerged. These were screened by PCR.
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2.14  Generation of KO mutants (homologous recombination) 
Reverse genetics allowed for the functional analysis of the cydDC encoded exporter in 
M. smegmatis. This involved creating a truncated version of the cydDC operon through 
homologous recombination, a technique described by (Gordhan and Parish, 2001). The 
final Kan marked ΔcydDC construct with selectable marker genes was mixed with 300 
L electrocompetent M. smegmatis cells while on ice and transformed as described 
previously (see 2.7.2). Cells were rescued in 2XTY and incubated with shaking 
overnight (30 C) for phenotypic expression of marker genes. Cells were harvested and 
re-suspended in 500 L of 7H9 and propagated on 7H10 supplemented with Kan and 
Xgal. Plates were incubated at 30 C for 4 days and blue colonies were picked and 
propagated in 7H9 with Kan. The culture was propagated to OD600 =2 and 70 L diluted 
serially in 7H9 (700 L) from 100-10-9. Dilutions were plated in duplicate on 7H10 (2% 
sucrose and 2% Xgal) and incubated at 37 C. White colonies were picked and spotted 
in 7H10 (XGal) and 7H10 (Kan, Xgal). Cells that appeared white on 7H10 (Xgal) and 
perished on 7H10 (Kan, Xgal) were taken forward as possible mutants for preliminary 
screen by PCR. This procedure is outline in Figure 2.3.  
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Primers for screening were designed such that one amplifies a portion of the upstream 
region, one amplifies portion of the downstream region while the third amplified a region 
within cydC, see Figure 2.4 below.  
 
Figure 2.3. Schematic illustration of the generation of knock out mutants by homologous recombination.
Blue colonies were cultured in 7H9 with Kan and cultivated to stationary phase. One mL of this culture was
sub-cultured in 7H9 and propagated to stationary phase. A ten fold serial dilution of this culture was
prepared and plated on 7H10 with and without sucrose. White colonies on 7H10 with sucrose were further
patched on 7H10 supplemented with Kan, Xgal and 7H10 without kan. Colonies that appeared white on
7H10 Xgal and die on Kan were potential mutants and were taken forward for screening. (Adapted from
Gordhan and Parish 2001)
Single Cross Overs
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Potential DCOs
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A schematic illustration of how homologous recombination occurs in the chromosome is 
depicted below in Figure 2.5. 
 
Figure 2.4. Diagrammatic illustration of the primer binding sites for preliminary screening of
potential mutants by PCR. A) Forward Primer 1 (FP_1) that binds upstream of the truncation
pairs with Reverse primer 1 (RP_1) to yield an amplicon of 220 bp. B) a primer that binds within
cydC pairs with RP_1 to yield an amplicon size of 340 bp. This region for binding of Int_1 is
missing from the cydDC deletion mutant.
US DS
220 bp
FP_1 RP_1
∆cydDC
A
US DS
340 bp
FP_1 RP_1Int_1
cydDC
B
Figure 2.5. Diagrammatic illustration of the two step allelic exchange. A vector that carries the upstream sequence of cydD
and the downstream sequence of cydC and additionally lacks the ability to replicate on its own is introduced M. smegmatis
mc2 155 by electroporation. Regions of homology hybridize leading to the generation of single cross overs (SCO) which
contains both the mutated allele, the wild-type allele and the selectable marker cassette. A double cross over (DCO) event
leads to the loss of the wild-type allele and selectable marker genes. (Adapted from Gordhan and Parish 2001)
cydDC
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2.15  Generation of KO mutants (Recombination genetic engineering - 
Recombineering) 
A plasmid (pNIT) encoding proteins for the RecET system needed for recombineering 
was extracted and profiled using restriction enzymes as previously described (see 
2.4.1, and 2.6.4). Wild type M. smegmatis was cultivated at 37 C overnight and 
prepared for transformations. Electro-competent M. smegmatis cells were transformed 
with atleast 1 µg of the pNIT plasmid as previously described (see 2.7.2). 
Transformations were incubated at 30 C, overnight to allow phenotypic expression of 
selectable marker genes. Transformations were plated on 7H10 Kan and incubated at 
30 C for 4 days. A single colony was cultivated in 2 mL 7H9 Kan to OD600 2. A 100 L 
of this culture was inoculated in a 100 mL 7H9 Kan and propagated to OD600 0.4 at 
which point the recombinase machinery was induced by adding iso-valero nitrile (1 L 
per 1 mL media). The culture was allowed to reach OD600 0.8-1, and harvested at 3901 
x g for 10 min. The culture was subsequently washed three times with 10% glycerol 
(v/v). Primers to amplify regions of homology in the substrate were designed and 
procured as previously mentioned (see 2.2). Amplification with the synthesized primers 
was performed by PCR as previously described (see 2.6.1) and a 2111 bp fragment 
was separated and visualized as previously described (see 2.8). The amplicon was 
concentrated and approximately 1 g of linear amplicon was electroporated as 
previously described (see 2.7.2). The electroporations were incubated at 37 C 
overnight for phenotypic expression of selectable marker genes. The transformants 
were harvested at 16162 x g for 2 min and re-suspended in 500 L sterile 7H9. The 
transformants were cultivated in 7H10, supplemented appropriately with Strp and 
incubated at 37 C for 4 days. Colonies were screened by PCR (Table 2.8) for 
sequencing and screening respectively. One primer, placed further upstream of the 
upstream region was designed and an internal reverse primer that binds within the 
streptomycin cassette was also designed. 
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Table 2.7 Mutant screening primers for homologous recombination strategy 
Primer name Sequence 5`-`3 Position  
US_Fwd TACCTGATCGCTGCGGTC Binds 52bp 
upstream cydD 
DS_Rvs GTGTCTGACGACTCGGTCGAC Binds inside cydC 
cydC Int Fwd_ TTTCCGGTGGTCCTGCTCGAC Binds 168bp 
downstream cydC 
 
Table 2.8 Recombineering sequencing and screening primers 
Primer name Sequence 5`-`3 Position  
Fwd_1 ATGTGCTGCAAGGCGATTAAG 100 bp 
upstream of 
the 350 bp of 
the upstream 
of the cydD 
sequence 
Fwd_2 TGCGGCGCTACCTGATCGCTG Binds within 
the 350 bp of 
the upstream 
region 
Fwd_3 ACTTCGCTGCTGCCCAAGGTT Overlaps the 
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350 bp region 
Strp within  GCCGAAGTATCGACTCAACTA Binds inside 
Strp cassette 
Strp_R GCT TCC CCT GGA GAG AGC 
GAG A  
100 bp 
downstream of 
the cydC 
downstream 
sequence 
Screening 
primers  
  
Gene Specific_F 
(Recomb) 
GTTCGTGTCGCTGAAGACCT  
1058 bp 
Gene Specific_R 
(Recomb) 
GGTGCTGTACTCGACCACCT 
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2.16  Southern blot analysis 
2.16.1  gDNA digestion 
Genomic DNA of wild type M. smegmatis, single cross over and potential mutants was 
digested overnight in a volume of 20 L with AatII and PstI respectively. Digests, 
including ƛ  marker IV, were separated in a 0.8% agarose gel prepared in 1X TAE at 80 
V for 120 min and visualized as previously described alongside a ruler.  
2.16.2  Electro-blotting 
The gel was soaked in a receptacle containing depurination solution (Solution I) made 
up of 0.2 M HCl and subsequently left to stand for 15 min with mild shaking every 5 min. 
Solution I was decanted into a waste bottle and the gel washed twice (mild shaking) for 
5 min with distilled water. The gel was then soaked in denaturation solution (Solution II) 
composed of (0.5M NaOH/1.5M NaCl) for 30 min with mild shaking every 5 min. 
Solution II was decanted into a waste bottle and 1X TBE used to equilibrate the gel (50 
mL 10X TBE + 950 mL dH2O). A nylon membrane was cut to the following dimensions: 
6.5 cm X 9.5 cm for DNA transfer. A transfer cassette was placed inside a glass dish 
and a sandwich set up as follows: first, two TBE soaked sponges were laid down 
followed by two TBE soaked filter papers, the gel was placed on the filter paper with 
wells facing up. The nylon membrane was properly aligned with the gel and two TBE 
soaked filter papers placed on the nylon membrane. A TBE soaked sponge was placed 
on top of the membrane followed by the top cover. The clips were engaged to close the 
cassette. The sandwich was transferred to a tank. Transfer was performed at these 
parameters: 90 V, current 600 A and time 120 min. Following transfer, the sandwich 
was dismantled and the membrane transferred to dry filter paper and crossed linked in a 
UltraViolet crosslinker for 2 min at 2470 kJ. Membranes were immediately hybridized. 
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2.16.3  Probe synthesis and labelling  
Probes were synthesized using primers that were used to generate the upstream region 
of the pcydDCKO knockout construct. The PCR probe synthesis kit (Roche) was 
employed to synthesize labelled probes by incorporating a labelled dioxygenin UTP. 
Fast start taq DNA polymerase was used to generate probes using the same cycling 
conditions as described before (see 2.6.1). An unlabeled probe amplicon was loaded 
alongside the labelled probe amplicon as a control to observe the increase in molecular 
weight due to incorporation of the DIG nucleotide. Probes were used immediately for 
hybridization. 
2.16.4  Hybridization  
Nylon membranes with DNA facing up were transferred to hybridization bottles (Hybaid 
HB-OV-BM) containing 10 mL pre-hybridization solution (DIG-EASY-HYB). The bottles 
were gently swirled to remove air bubbles and placed inside the hybridization oven 
(Hybaid Micro-4) at a hybridization temperature of 56°C for 30 min. The hybridization 
temperature was calculated using the equation: 
 
 
 
 
 
The PCR synthesized probe was denatured at 95 °C for 5 min and immediately placed 
on ice. The probe was then added at a v/v of 2 L per 1 mL pre-hybridization solution. 
Hybridization was done overnight at 56 °C. The spent hybridization solution with probes 
was decanted into a falcon tube and stored at -20 °C for future use. Membranes were 
carefully removed from the hybridization bottles and subjected to 15 min of two stringent 
washes with 20 mL solution I at 56 °C (10 mL of 20X SSC, 1 mL 10% SDS and 89 mL 
T
m
= 49.82+0.41(%GC) – 600/L 
T
opt
 = Tm-20 °C     
Where Tm = Melting temperature 
L =length of the probe 
GC= % of Guanine to Cytosine  
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dH2O) and 20 mL solution II at 68 °C (2.5 mL, 20X SSC, 1 mL 10% SDS and 96.5 mL 
dH2O). 
2.16.5  Immunological detection 
Membranes were rinsed in wash buffer for 5 min (100 mL 20X maleic acid, 3 mL Tween 
20 in 1L of dH2O) and were subsequently incubated in 25 mL blocking solution for 30 
min with intermittent shaking (90 mL wash buffer + 10 mL 10X blocking solution). The 
blocking solution was decanted and the membranes incubated in 25 mL antibody 
solution (50 mL blocking solution + 5 L anti-digoxygenin antibody) for 30 min. The 
membranes were washed twice in wash buffer for 15 min and equilibrated in 20 mL 
detection buffer (0.1M Tris HCL, 0.1M NaCl pH 9.5) for 5 min. The membranes were 
then transferred to hybridization bags (DNA facing up) and 1 mL substrate (CSPD) 
added and spread over the surface. Excess CSPD was squeezed out and the 
hybridization bags were sealed and incubated in the dark for 10 min at ambient 
temperature. The blots were exposed to X-ray film for 10 min in the dark and developed 
by washing the film in developing solution for 30 sec, in dH2O for 30 sec, in fixative 
solution for 30 sec and again in dH2O for 30 sec. The films were allowed to air dry for 2 
min. 
2.17  Lysis of E. coli cells for preparation of membrane fractions 
To establish the functionality of the cydDC operon, heterologous expression of Mtb 
genes in E. coli was performed. Lysis of E. coli cells was performed as previously 
described (Cox et.al., 1973). The E. coli K12 strain and its derivatives were 
homogenized using a sonicator. For this, the probe of the sonication system was first 
washed in 100% ethanol by pulsing for 5 min and the probe rinsed with dH2O for an 
additional 5 min. Cells (4g wet weight) were washed twice in 0.1 M Tris-HCl pH, 7.4 
were re-suspended in 20 mL of the same buffer. The 50 mL falcon tube containing cells 
were placed in a small beaker with crushed ice and 100% ethanol. Cells were placed 
inside a soundproof booth with the probe sonicator. The probe was dipped into the 
falcon tube containing cells and ultrasonic wave parameters set as follows for lysis: 
time-20 min, cycle-6, power, 0.99. Cells were subsequently homogenized at these 
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parameters and cooled on ice for 10 min between each lysis step. 8-10 steps of lysis 
were performed before membrane fractions were extracted.  
2.17  Lysis of M. smegmatis cells 
M. smegmatis cells were lysed for extraction of membrane fractions as previously 
described (Guttman., et.al 2009). For the functional analysis of the cydDC, M. 
smegmatis and its derivatives were homogenized using a French Press. Parts of the 
FrenchPpress system were washed with dH2O and allowed to chill at 4 °C. The piston 
was inserted up to the ―Max fill‖ into the cylinder, which was turned upside down and 
place into the tripod. The needle valve was screwed into the piston head and the flow 
through pipe tightly screwed on. Cells were transferred to the cylinder leaving a 1 cm 
head space and an empty 50 mL falcon tube was connected to the cap of the flow 
through tube. The piston head was fitted over the filled cylinder while supporting the 
piston handle with the other hand. The cylinder, held in the correct position, was then 
transferred to the pressure chamber. The needle valve on the piston head was 
tightened and the device was turned on. The lever was engaged to the medium position 
and the right side dial was used to adjust the pressure to 2.7 kpsi. A small drizzle into 
the falcon tube was observed and the entire complex was lowered down by pushing the 
lever to the down position. The falcon tube was unscrewed and placed on ice. The 
complex was removed from the French press and the piston pulled to the ―max fill‖ 
mark. Membrane fractions were extracted from lysed cells by ultracentrifugation (see 
2.18). 
2.18  Purification of membrane fractions by ultracentrifugation 
Alternatively, 100 mL of cells were harvested and re-suspended in 20 mL EDTA wash 
buffer (50 mM HEPES-KOH, containing 20 mM EDTA and 10% glycerol pH7.0) and 
cells were homogenized using a sonicator. Cells were incubated at room temperature 
(30 min) with casual stirring. Cell were harvested at 5755 x g for 10 min and re-
suspended in 10 mL lysis buffer, supplemented with 0.1 mM PMSF and proteinase 
inhibitor cocktail (50 mM HEPES-K, containing 150 mM KCl, 10% glycerol pH 7.0) and 
homogenized in a sonicator (max power, 20 min and 4 cycles). The cell lysate was 
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incubated at 37 °C for 120 min with gentle stirring and sonicated as follows (On for 1 
min (as previously described 2.17), and placed on ice for 3 min) for 20 cycles. The 
supernatant was harvested at 7 674 x g for 20 min at 4 °C and pooled into 
ultracentrifuge tubes. The supernatant was clarified at 17 266 x g for 20 min at 4 °C. 
The centrifugation step was repeated. The resulting supernatant was ultracentrifuged at 
38 369 x g for 60 min at 4 °C. The reddish transluscent pellet was re-suspended in 
membrane purification buffer (50 mM HEPES-KOH, containing 300 mM KCl, 2 mM 
MgCl2 and 20% glycerol pH 7.0) and was subsequently centrifuged at 38 369 x g for 40 
min at 4 °C. The membranes were re-suspended in minimal volume of membrane 
purification buffer.  
Alternatively, membrane fractions obtained by lysis with a French press were purified as 
described by (Kana et al., 2001). Membrane fractions were collected by 
ultracentrifugation at 17 266 x g. The supernatant was further clarified by 
ultracentrifugation at 47 962 x g. The supernatant from this preparation was used as 
membrane containing fraction and was used for membrane spectroscopy. 
2.19  Phenotypic characterization of Mutants 
2.19.1  Membrane spectroscopy E. coli and M. smegmatis 
To determine the presence of the spectroscopic features associated with a functional 
CbdO, membrane spectroscopy was performed. The Cary4E dual beam 
spectrophotometer was first blanked with two cuvettes containing re-suspension buffer. 
Membrane fractions (3 mL) were transferred to an electroporation cuvette and were 
oxidized with potassium ferricyanide and reduced with grains of sodium dithionate. The 
reduced minus oxidized spectra were recorded at room temperature using the Cary4E 
spectrophotometer.  
2.19.2  Response to induced oxidative stress 
Response to oxidative stress was tested using a modified protocol described by (Poole 
et al., 1989). M. smegmatis mc2 155 and its derivatives were assayed for survival upon 
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exposure to 2% exogenous hydrogen peroxide (H2O2). For this, M. smegmatis mc
2 155, 
M. smegmatis ΔcydDC, ΔcydDC::pMVpcydDC were cultured (see 2.3) in a shake flask 
to OD600 = 0.1 and a 10-fold serial dilution performed on each strain in triplicate and 
plated on plain 7H10 media for unmarked strains and selective 7H10 for the 
complemented strains. The plates were incubated at 37 °C for 48-72 hrs. CFUs were 
enumerated to assess survival upon exposure to exogenous H2O2. Similarly E. coli and 
its derivative strains were cultured to an OD600 0.2 and assessed for the ability to 
survive exposure to 2% exogenous H2O2. A 10 fold serial dilutions of the peroxide 
exposed culture were plated on LA supplemented appropriately with Hyg for marked 
strains and on plain LA for unmarked strains. Plates were incubated at 30 °C for 24 hrs 
and CFUs were enumerated to assess survival. 
2.19.3  Growth curves 
Growth trend analysis was performed as described by (Kana et al., 2001). Growth 
trends of M. smegmatis and its derivatives were assessed in 7H9 in a Bioflow 110 
fermenter at 21 % and 0.7% dissolved oxygen as previously described (see 2.3) for 24 
hrs. For every strain, growth was first monitored at 21 % dissolved oxygen. The 
fermenter was allowed to stabilize at the set dissolved oxygen limit for atleast one hour 
before decreasing the oxygen tension to 5% and finally to 0.7%.  OD readings were 
taken every three hours and viable counts were determined by plating dilutions of a 
certain range as determined by OD readings. The plates were allowed to dry in a class 
II biosafety cabinet and incubated at 37 °C for atleast three days. Plates were observed 
for growth and CFUs were enumerated. 
2.19.4  Temperature sensitivity assays 
The temperature sensitivity assay was done as described by (Kana et al., 2001). The 
ability of E. coli and its derivative strains to grow at high temperatures was investigated. 
E. coli and its derivative strains were cultivated to stationary growth phase (OD600 2) by 
incubating at 37 °C with spinning (110 rpm). A 10-fold dilution series of the stationary 
phase cultures was performed. Dilutions were plated with and without selection. Plates 
were allowed to dry in a Class II biosafety cabinet and subsequently incubated at 42 °C. 
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Plates were examined for growth and CFUs were enumerated. A student T test was 
employed to determine statistical difference between the data set. 
2.19.5  Nutrient starvation assays for E. coli  
The nutrient starvation assayed was done as initially described by (Siegele and Kolter, 
1993). The ability of E. coli and its derivatives to exit from stationary phase was 
investigated. The premise here is that at stationary phase, the bacteria experience 
nutrient runout. A seed stock of E. coli and its derivatives were cultured M63 glucose 
minimal media. The cultures were incubated at 37 °C with spinning (110 rpm) for up to 
10 days. A 10-fold dilution series of the starved cultures was performed and the 
dilutions were plated on M63 agar. Plates were allowed to dry in a class II biosafety 
cabinet and incubated at 37 °C for 24 hrs. Plates were observed for growth and CFUs 
were enumerated from dilutions 10-6 to 10-8. A student T test was employed to 
determine statistical significance between the data set.  
2.19.6  Nutrient starvation assays for M. smegmatis 
The ability of M. smegmatis and its derivatives to exit from stationary phase was 
investigated as described by (Siegele and Kolter, 1993). The premise here is that at 
stationary phase, the bacteria experience nutrient depletion. Cultures of M. smegmatis 
and its derivatives were cultured in sautons media which is a minimal concoction for 
mycobacterial growth. The cultures were incubated at 37 °C with spinning (100 rpm) for 
up to 10 days. A 10-fold dilution series of the starved cultures was performed and the 
dilution series plated on 7H10 with 0.05% glucose. Plates were allowed to dry and 
incubated at 37 °C for 24 hrs. CFUs were enumerated from dilutions 10-6 to 10-8. A 
student T test was employed to determine statistical significance between the data set. 
2.20  Data analysis 
The student t-test was used to analyze data. A p-value less or equal to 0.05 was 
considered statistically significant. 
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3. Results 
3.1 The cydC gene in M. smegmatis encodes a functional protein 
Upon retrieving the nucleotide sequence of cydC to use for targeted gene deletion, it 
was noted according to the Smegmalist database, that cydC did not encode a functional 
subunit due to a point mutation in the open reading frame. Previous work from our 
laboratory on CbdO suggested that our laboratory strain of high electroporation 
efficiency, M. smegmatis mc2 155, encodes a functional holo-enzyme for CbdO (Kana 
et al., 2001, Snapper et al., 1990). To further substantiate this, the relevant region in 
cydC was amplified by PCR (with genomic DNA from the laboratory mc2155 wild type 
strain) and digested with an enzyme that cuts asymmetrically to confirm that region 
specific amplification occurred, Figure 3.  
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The amplicon was sequenced and sequence data was analyzed with a multiple 
sequence alignment tool, Clustal Omega. The reference sequence used was the cydC 
nucleotide sequence retrieved from the Smegmalist database designated, M. 
smegmatis _cydC_ref, in Figure 3.1. The reference sequence was aligned against the 
sequences generated by designing primers that span the cydC genetic region denoted 
as cydC_cydC_ forward primer (FP), cydC_cydC_internal primer and 
cydC_cydC_reverse primer (RP), the positions of which are shown in Figure 3. The 
multiple alignment revealed that the sequence resulting from the genomic DNA of our 
laboratory strain harbor no point mutations and as such, mc2155 encoded a functional 
cydC gene, the function of which could be interrogated further in this study (Figure 3.1).  
Figure 3. (a) PCR amplification of full length cydC including a 100 bp of upstream and
downstream sequence using a high fidelity polymerase. Amplicon (1743 bp) was
separated on a 1% agarose gel by electrophoresis for 50 min and visualized under ultra
violet light. There is a twelve bp region of overlap between cydD and cydC indicating
that they are operonic. The three lanes represents three replicate PCRs. (b) Restriction
digest of cydC amplicon with MluI to confirm gene targeted amplification. Restriction
digest gave expected band sizes.
2176 bp
1766 bp
1230 bp
1033 bp
653 bp
517 bp
453 bp
394 bp
294 bp
154 bp
MVI MluI
1085 bp
658 bp
B
1743 bp2176 bp
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517 bp
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394 bp
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A
cydCcydD
cydC-cydC_ FP cydC_cydC_RP1743 bp 
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Notably, both the internal primer and the reverse primer had numerous errors at position 
146, however, the FP had consistent correct read outs. To substantiate sequencing 
data, the cydC region was edited and translated using Exparsy translate tool to 
determine if the removed insertions encoded a functional polypeptide (Figure 3.1.1). 
 
Figure 3.1. Multiple sequence alignment using Clustal Omega to prove that cydC encodes a
functional polypeptide. The nucleotide sequence of cydC was retrieved from Smegmalist and
aligned with a template sequence generated from primers designed every 500 bp to span the entire
gene (1543 bp). Sequence data suggests that there is a cytosine and guanine insertion (circled in
red) which is not present from the template synthesized with a high fidelity polymerase from our
laboratory stock of high efficiency M. smegmatis wild-type cells.
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This yielded the necessary evidence to confirm that our laboratory strain of wild-type M. 
smegmatis encodes a functional protein thus providing the opportunity to study the 
function of this transporter in M. smegmatis. The cydC and cydD genes are operonic in 
M. smegmatis as the stop codon for cydD overlaps with the start codon for cydC 
(information obtained from Smegmalist) (Aung et al., 2014). Studies in the published 
literature on various microorganisms report only on single deletions of the ABC 
Figure 3.1.1. Bioinformatic analysis on the cydC region. Nucleotide sequence of cydC was retrieved
from Smegmalist and mapped for nucleotide insertions identified using sequencing. According to
sequence data, several primers report a cytosine and a guanine insertion at position 16 and 146 which
creates a frameshift mutations resulting in stop codons that affect the encoded polypeptide. (A )
Unedited cydC region showing in green Methanione signalling translation start site and in red, reported
insertions. (B) Edited cydC region with insertions removed and (C) translation of both the edited and
unedited cydC region using exparsy. This data proves that our laboratory strain of wildtype M.
smegmatis cydC open reading frame encodes an intact subunit.
1 ttgttgcgccatgatccgttgctccgcctgaccctcgagctgttgcgtccccggctcgggcggttcctgctggccgcggc 80 
 
81 gctcggggtgctctcgctgggcagcgcactggcgttggcggggatctcggcgtggctgatcacccggcgcctggcagatg  160 
 
161 ccgcccgtgctggatttgaccgtcgcggtggtggcggtgcgcgcgctgggcatctcccgcggcgtcctgggctactgcca  240 
cydC with insertion mutations
Unedited cydC
Edited cydC
A
C
B
1 ttgttgcgccatgatcgttgctccgcctgaccctcgagctgttgcgtccccggctcgggcggttcctgctggccgcggc 80 
 
81 gctcggggtgctctcgctgggcagcgcactggcgttggcggggatctcggcgtggctgatcacccgcgcctggcagatg  160 
 
161 ccgcccgtgctggatttgaccgtcgcggtggtggcggtgcgcgcgctgggcatctcccgcggcgtcctgggctactgcca  240 
cydC insertions removed
Translation of the cydC region with exparsy
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transporter pair (cydD or cydC) (Georgiou et al., 1987, Poole et al., 1989). In addition, 
the phenotypes associated with these deletions are variable and sometimes difficult to 
explain (Georgiou et al., 1987, Poole et al., 1989). Based on this, it was decided in this 
study to generate a double deletion of the putative ABC transporter for functional 
analysis in M. smegmatis. However, before embarking on this, we first did modeling of 
the three-dimensional structure of the CydDC-encoded ABC-type transporter using 
online modeling tools (see section 2.1) to further understand the topology of these 
subunits. 
3.2 Modeling the CydDC subunits  
The first task of this study was to understand the structure and the configuration of the 
conserved residues within the helical ABC domain of the putative cydDC-encoded ABC-
type transporter in M. smegmatis. Protein sequences of both CydD and CydC were 
retrieved from Smegmalist and deposited into ITASSER for structural threading, which 
was carried out with 100% confidence for 95% of the modeled residues. Conserved 
residues associated with the ABC domain were identified and labeled (Figure 3.2). 
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The identification of conserved residues proved irrevocably that in mycobacteria, the 
CydDC retained conserved residues in the helical domain, which define ABC-type 
transporters. All of the conserved residues in the helical domain were easily identified. 
However, the signature motif, designated the LSGGQ motif in most bacteria was 
missing in both the CydD and CydC. This prompted us to do a multiple alignment with at 
least 10 unique CydD protein sequences from different bacteria, Figure 3.3. Four of 
these ten sequences were from the actinobacteria phylum and three belonged to the 
genus mycobacteria.  
II) cydC
sub-unit
I) cydD
sub-unit
Walker A
GxxGxGKST
Walker B
xxxxDEPT
Q-loop
xxQxx
Signature
LSLGQ
H-loop
xxHxx
Walker B
Walker A
H-loop
Q-loop
Figure 3.2. Structural prediction of subunit III (CydD) and subunit VI (CydC) encoding
the putative ATP Binding Cassette (ABC) type transporter in M. smegmatis using
ITASSER. The conserved residues in the helical domain as outlined in the colour coded
scheme, were identified to verify that the cydDC indeed encode members of the ABC
type transporter. A) Structural configuration of conserved residues within the helical
ABC domain. B) Structural prediction and mapping of conserved residues within the
helical ABC domain.
A
B
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The alignment revealed that the highly conserved LSSGQ motif in other bacteria was 
indeed present in mycobacteria, but had evolved to an LSLGQ variation of the 
conserved motif. As this represented a relatively minor change with the prevailing 
consensus sequence, we propose that this motif is indeed conserved in mycobacteria 
and we have modeled it on to the three dimensional structure (yellow color in Figure 
3.3). Collectively, these observations with the sequence information from our laboratory 
stock confirmed that M. smegmatis encodes a functional CydDC ABC-type transporter 
in mycobacterial species. 
To interrogate the function of the CydDC subunits in M. smegmatis, we adopted the 
heterologous expression approach in E. coli where the transporter is best characterized. 
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3.3 Construction of a plasmid carrying the Mtb cydDC genes for heterologous 
expression in E. coli 
To provide preliminary evidence and to further probe the function of this putative 
exporter, an over-expression system carrying the whole Mtb cyd operon was 
constructed. The approach in this case was to use the Mtb and M. smegmatis cydDC 
genes to complement the phenotypic defects of an E. coli ΔcydD mutant. The ability of 
the mycobacterial genes to reverse the defects of the E. coli mutant would provide 
further evidence that these genes indeed encode a functional ABC-type transporter. 
Hence, the homologous Mtb region was digested from a cosmid library (pOTBcyd) to 
yield a fragment carrying the entire Mtb cyd operon. The plasmid was digested with 
BamHI and HindIII as previously described (See 2.6.4) to release the entire cyd operon 
which was subsequently cloned into an over-expression vector (pSE100) which was 
initially verified by restriction profiling and linearized with BamHI and HindIII. A ligation 
reaction was carried out including the following controls: cells only control, linearized 
vector control, and the uncut vector control. The ligations were transformed in E. coli 
DH5α and plated on LA supplemented with Hyg. A few colonies were screened by 
restriction digest for recombinant plasmid (data not shown). The final complementation 
construct (clone 5) was profiled with several enzymes to verify the integrity of the 
plasmid (Figure 3.4).  
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A pre-culture of E. coli ΔcydD (1 mL) was inoculated in fresh LB and cultivated to OD600 
0.5. The culture was washed twice in 0.1 M calcium chloride. At least 1 µg of clone 5 
was subsequently transformed in calcium chloride competent E. coli ΔcydD culture. The 
transformants were selected in LA supplemented with Hyg as previously described (See 
2.7.1). The colonies were propagated in LB supplemented with Hyg and the episomal 
overexpression vector was extracted as previously described (See 2.4.3) and the 
recombinant plasmid was digested with a few restriction enzymes for verification 
purposes (Appendix A10). 
5148 bp
1584 bp
925 bp
21226 bp
4268 bp
2027 bp
1375 bp
831 bp
564 bp
MIII Uncut BamHI BspHI EcoRI PvuI PvuII SmaI
2965/
2741 bp
7973 bp
913 bp
1792 bp
8886 bp
2306 bp
6580 bp
4525 bp
1400 bp
2961 bp
4532 bp
2039 bp
1085/
1035 bp 1322*
Figure 3.4. Restriction profile of the overexpression construct to be used for heterologous expression
separated on a 1% agarose gel. From left to right: Lane 1-2, Marker III and uncut pSE control
respectively. Lane 3-8 BamHI, BspHI, EcoRI, PvuI, PvuII and SmaI digests respectively. All digest
except for the smaI digest marked with an asterix gave the expected band sizes. This band was slightly
lower than it should be.
Enzyme Expected band sizes (bp)
BamHI 8886
EcoRI 2306, 6580
BspHI 1400, 2961, 4525
PvuI 1085, 1035, 165 2039, 4532
PvuII 913, 7973
SmaI 2965, 2741, 1792, 1322, 66
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3.4 Construction of a plasmid carrying the M. smegmatis cydDC genes for 
heterologous expression in E. coli  
The M. smegmatis cydDC operon was also assayed for heterologous expression in E. 
coli cydD null mutant. The cydDC operon was excised from a plasmid designated as 
―clone 29‖. SmaI restriction sites were identified as suitable for excising the cydDC 
operon including up to 300 bp of upstream nucleotide sequence of cydD. Blunt cloning 
into pMV306H was carried out using EcoRV to linearize the vector. The fragments were 
separated by agarose gel electrophoresis in a 1% agarose gel. Before cloning, gel 
purified fragments were separated and visualized once more to estimate the amounts 
needed for cloning. As routine, experimental controls that enabled effective 
troubleshooting included cells only, uncut plasmid and cut and ligate control. The 
cloning procedure was carried out overnight at ambient temperature using the NEB 
cloning kit as previously described see 2.6.8. Ten (10 µL) the cloning reaction was 
transformed in calcium chloride competent E. coli DH5α cells as previously described 
see 2.7.1 and the remaining stored at -20 °C. Single colonies that emerged were sub-
cultured in LB supplemented appropriately with Hyg and cultivated overnight at 30 °C. 
Plasmid DNA was extracted following the mini prep protocol as previously detailed see 
2.4.3. The extracts were profiled with two enzymes to screen for recombinants (data not 
sown). Clone 12 was taken forward for large-scale DNA extraction and profiled 
thoroughly with various restriction enzymes (Figure 3.5). All digests gave corresponding 
band sizes (Figure 3.5).  
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Restriction mapping confirmed that plasmid was correct and could be used for 
subsequent heterologous expression experiments. It should be noted that this plasmid 
was generated after the Mtb heterologous complementation vector. As a result the first 
two experiments to test heterologous complementation (growth kinetics and membrane 
spectroscopy) and was done only with the Mtb genes. Thereafter, both the Mtb and M. 
smegmatis genes were tested by heterologous expression in the E. coli ΔcydD mutant.  
 
 
Figure 3.5. Restriction profile of ΔcydDC complementation construct designated clone 12 with various restriction
enzymes. (A) Clone manager map for the virtual construction of ―clone 12‖. (B) Restriction profile of clone 12 with
various restriction enzymes. Fragments were separated on a 1% agarose gel by electrophoresis and visualized by
the GeneSnap software. Loaded from left to right: lane 1&2 Marker III and uncut respectively, lane 3-8 BamHI, BglII,
EcoRI, MluI, PstI and PvuII digests respectively. All digests yielded expected band sizes as annotated. (C) Selected
enzymes for digestion and expected band sizes.
6285 bp
1167 bp
711 bp
5140
3023 bp
5305 bp
4387 bp
2858 bp 2622 bp
1055 bp
5558 bp
1100 bp
753/ 734 bp
8163 bp
5148 bp
1584 bp
925 bp
21226 bp
4268 bp
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3.5.  Heterologous expression of the Mtb putative transporters restores CbdO 
biogenesis in E. coli. 
The E. coli ΔcydD strain was complemented with the previously described Mtb genes. 
The resulting ΔcydD(pSE:pGcyd) complemented strain was assayed for the ability to 
restore the loss of CbdO associated spectral features in the ΔcydD E. coli strain. E. coli 
strains were grown in the Bioreactor at 1% air saturation as growth under hypoxic 
conditions allows for maximal biosynthesis of the CbdO, making is easier to detect by 
membrane spectroscopy (Kana et al., 2001). A diagnostic feature for the presence of a 
functional CbdO is the chlorin heme d molecule, which can be detected at a wavelength 
of 628-630 nm in the α-band by membrane spectroscopic analysis (Kita et al., 1984). As 
expected, this peak was absent in the ΔcydD E. coli strain, (Figure 3.6.)  
 
Figure 3.6. Absorption difference spectroscopy using the Cary 4E spectrophotometer. Reduced minus
oxidized spectra of E. coli membrane fractions purified by ultracentrifugation. From top to bottom, aligned
spectra of: (A) wild-type showing the presence of the heme d peak at 630 nm (pointing blue arrow) (B)
ΔcydD characterized by the spectral loss of the chlorin heme d peak (yellow arrow) and (C)
ΔcydD(pSE:pGcyd) reconstitution of cydD with an episomal plasmid carrying the entire Mtb cyd operon (red
arrow). The data show that spectral features associated with the holoform of CbdO is present in (A), wild-
type E. coli and (C), Heterologously expressed Mtb ΔcydD(pSE:pGcyd) showing that Mtb cyd genes are
able to restore the loss of CbdO.
Figure 7. Membrane spectra of the three E. coli strains. A) Wildtype E. coli showing the presense of 
the heme d peak (628-630 nm) B) deletion of cydD s characterized by the d sappearance of the chl rin d 
peak. C) heterologous expression with the mycobacterial cydDC operon restores the chlorin d peak.
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Ectopic over-expression of the Mtb putative ABC transporter-encoding cydDC genes 
restored diagnostic the heme d peak in the membrane spectrum, thus confirming 
functional CbdO biogenesis (Figure 3.6). The reduction in the expression of other 
cytochromes was also restored by heterologous expression.  
3.6 Growth kinetic analysis of E. coli and its derivative strains 
Following spectroscopic analysis of heterologously expressed putative ABC type 
transporters, we assessed the growth rates of the E. coli strains to ensure the increased 
expression of the mycobacterial genes did not adversely affect the growth of the ΔcydD 
E. coli strain. This was necessary as some of the experiments to test heterologous 
complementation could be affected by defective growth of the heterologous strain. To 
investigate this, the growth of E. coli and its derivative strains under normoxic conditions 
was assessed by growth curve analysis. Cells were inoculated either from a seed stock 
or from a single colony to prepare a pre-culture from which the experiment was 
performed. E. coli and its derivative strain were inoculated from an overnight pre-culture 
to an OD600 0.01 and OD readings were determined at 30 min intervals. Each strain was 
assayed in triplicate and each graph represents a mean of three independent 
experiments (Figure 3.7).  
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Ectopic expression of the Mtb genes in E. coli yielded similar growth patterns to wild-
type under normal growth conditions and as cells entered stationary growth phase 
(Figure 3.8). However, as the cell population increased and nutrients got depleted, the 
cydD null mutant exhibited what appeared to be a growth defect phenotype (Figure 3.7) 
as exemplified by poor turnover in biomass at the onset of stationary phase. This 
reduced biomass was not statistically different to the wild type with a p-value of 0.16 
determined by the student t-test.  
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Figure 3.7. Growth kinetics of E. coli and its derivative strains for 8hrs30 min. (A) wild-type (Blue trendline)
(B) ΔcydD (Red trendline) and (C) ΔcydD(pSE:pGcyd) (Green trendline). Notably, ΔcydD experiences a
growth defect as the cultures approach stationary growth phase as noted by the failure to significantly increase
in biomass over time. On the other hand, the Mtb complement displays a similar growth trend to wild-type.
However, no statistical difference was observed between the growth of E. coli and its derivatives when the
data were analyzed by the student t-test. P value= 0.16. This data represents one experimental replicate of
each strain performed in the bioreactor.
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3.7 Heterologous expression to assess the stationary growth phase arrest 
phenotype 
To further probe the growth defect observed in the E. coli ΔcydD strain during growth 
analysis, further analysis of growth recovery in stationary phase was carried out. It was 
previously reported that strains lacking CydC (previously isolated as SurB-) experienced 
stationary growth phase arrest and as such could not exit from stationary phase at 
higher temperatures (Siegele and Kolter, 1993). At this point, a plasmid for heterologous 
expression of the M. smegmatis cydDC genes (pMV::cydDC) was generated and 
included in the analysis. Hence, we asked the question: can heterologous expression of 
Mtb or M. smegmatis putatitve ABC type exporters rescue the stationary arrest 
phenotype? This would unequivocally prove that the both transporters phenocopy their 
counterparts found in E. coli. For this, a seed stock of E. coli and its derivative strains 
were inoculated in glucose minimal media and cultivated to stationary phase as detailed 
in (2.19.5). The cultures were incubated at 30 °C for up to 10 days. A 10 fold serial 
dilution of each strain was performed and plated on M63 plates. The plates were 
incubated for 24 hours at 37 °C and assessed for growth (Figure 3.8).  
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Following the 24 hour incubation probation, all plates had growth, but a stationary arrest 
phenotype was clearly discernable from the plating efficiency with regards to ΔcydD 
strain relative to wild-type (Figure 3.8). Although the colony size of ΔcydD strain was 
unaffected, the number of platable CFUs were dramatically reduced relative to wild-type 
and the M. smegmatis heterologous complement. Complementation with the Mtb genes 
did not restore stationary phase recovery, which was surprising as this strain showed 
restoration of the heme d peak, associated with functional CbdO. The difference 
between wildtype and E. coli and ∆cydD was statistically significant (p value of 0.02) as 
determined by the student t-test. 
0
2E+11
4E+11
6E+11
8E+11
1E+12
1.2E+12
Wildtype ΔcydD ΔcydD::pMVcydDC ΔcydD(pSEpGcyd)
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Figure 3.8. Nutrient starvation assay in E. coli and its derivative strains including wild-type (3561), ΔcydD
(3562), ΔcydD::pMV_cydDC and ΔcydD(pSE:pGcyd). Following 24 hour incubation period, all plates had
growth but a stationary phase defect was evident in the ΔcydD strain. The ΔcydD::pMV_cydDC strain was
able to exit from stationary phase arrest better than the Mtb pGcyd complement. Error bars from this this data
represents a standard deviation between two experimental replicates. Data analysis revealed statistical
significance between wild type E. coli and the ΔcydD strain
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media and starve for 
10 days
Plate
P=0.02
P=0.15
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3.8. Heterologous expression to assess the temperature sensitivity defect of 
the E. coli ΔcydD strain  
Previous studies demonstrated that E. coli mutant that lacks either cydD or cydC is 
unable to form colonies at 42 °C. To establish if supplementation with the mycobacterial 
counterparts is able to reverse this defect, E. coli and its derivative strains were 
assayed for growth at high temperatures as previously described (2.19.3). Following 24 
hrs of incubation at 42 °C, the plated dilutions from 10-7 across to 10-9 were examined 
for growth from three independent biological replicates. Across all three independent 
experiments, the cydD null mutant had distinct growth with reduced colony morphology 
and plating efficiency relative to wild-type (Figure 3.9).  
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This defect was reversed to wild type levels when the E. coli mutant was complemented 
with the M. smegmatis cydDC genes. However, as observed with the stationary phase 
defect, heterologous complementation with the Mtb genes did not reverse the 
temperature sensitivity defect.  
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Grow to OD600 2
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Figure 3.9. Assaying for the ability of E. coli and its derivative strains to grow at high temperatures. Serial
dilutions of cultures cultivated to stationary phase were allowed to dry and subsequently incubated at 42  C
for 24 hrs. Wild-type (3561) grows better than ΔcydD mutant (3562) at higher temperatures. Heterologous
expression with the M. smegmatis exporter is able to rescue sensitivity due to high temperature while the
Mtb transporter fails to confer growth at higher temperatures.
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3.9  Heterologous expression is able to restore sensitivity towards exposure to 
exogenous hydrogen peroxide 
The respiratory burst is one mechanism that the host immune response employs to 
eradicate intracellular pathogens such as Mtb. It involves the release of antimicrobial 
agents such as reactive oxygen intermediates, which exerts oxidative stress on infecting 
bacteria. It is well established that the E. coli cydD mutant is sensitive to exogenous 
H2O2 treatment (Goldman et al., 1996a). Next, we assessed if heterologous expression 
of the cydDC exporter from the two mycobacterial species can desensitize the oxidative 
stress phenotype observed in E. coli due to cydD loss. To mimic oxidative stress, 
challenge with H2O2 was carried out as described in section (2.19.2). To confirm that the 
E. coli  ∆cydD mutant is sensitive to treatment with H2O2 after 15 min and 30 min 
(Figure 3.10).  
 
Figure 3.10. Survival of E. coli and its derivative strains in the presence of
exogenous hydrogen peroxide (H2O2). E. coli and its derivatives were assayed for
sensitivity to exogenous H2O2 (2%) at different time points (15 and 30 min). Each
graph represents a mean value of three independent replicates for each strain. The
error bars represent standard deviations. Notably, ΔcydD was sensitive to H2O2. Error
bars represent a standard deviation of three experimental replicates. This data were
statistically significant as shown by a p value of 0.02 between wildtype and the cydD
mutant. Heterologous expression of the M. smegmatis putative exporter rescued this
phenotype. Heterologous expression of the Mtb genes failed to complement this
phenotype.
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Heterologous complementation with the M. smegmatis cydDC genes completely 
rescued this phenotype, while heterologous expression of the Mtb transporter failed to 
complement the defect (Figure 3.10). It is unclear why the Mtb cydDC genes were 
unable to restore some of the defects in the E. coli ΔcydD mutant. The most likely 
explanation that is sufficient levels of expression were not achieved or that over-
expression caused some toxicity effect. Due to time constraints this was not 
investigated further.  
Collectively, protein modeling, stationary phase recovery assays, temperature sensitivity 
assays and oxidative stress assessment provided unequivocal evidence that the M. 
smegmatis cydDC genes encoded a functional transporter. To further investigate the 
biological role of the cydDC genes in M. smegmatis, these genes were targeted for site 
specific deletion. Two approaches were taken to construct a knockout mutant. The first 
was allelic exchange using a suicide plasmid (described in section 2.14 of the Materials 
and Methods) and recombineering (using the lamba red recombinase described in 
section 2.15 of the Materials and Methods).  
3.10 Construction of an in-frame double deletion mutant of the M. smegmatis 
that lacks the cydDC operon. 
Gene knock out primers (Table 2.4) were designed as outlined in (See 2.6.1) Upstream 
and downstream regions were PCR amplified as previously described (See 2.6.1) and 
the amplicons were verified by restriction analysis (Figure A 10). A cloning vector was 
also verified by restriction digest before cloning (data not shown). First, the three way 
cloning strategy into pBlueScript was carried out. White colonies were sub-cultured in 
liquid and screened with various restriction enzymes (Figure A10). The insert containing 
the cydDC deletion allele and associated homologous regions for gene editing was 
recovered as a 2007 bp HindIII fragment and sub-cloned into p2NIL which was 
previously digested with HindIII. White colonies were sub-cultured in broth and 
subsequently screened (Figure A10).This suicide construct was sent for sequencing to 
ensure that no mutations were carried on both the upstream and downstream region 
during PCR amplification. Sequencing data showed that the amplification procedure 
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was carried out with high fidelity and with no mutations in the amplified genomic regions 
(Figure A 10). Selective marker genes in the pGOAL17 plasmid were excised and 
cloned as a PacI. The putative clones were plated on LA supplemented with Xgal. The 
plates were incubated at 30 °C to prevent plasmid re-arrangement. Blue colonies were 
picked and sub-cultured for bulk DNA extraction. The 13119 bp final construct was 
profiled as previously described (See 2.6.4) (Figure 3.11).  
 
 
Plasmid digests yielded corresponding expected band sizes, Figure 3.11. Two 
unexpected bands in the HindIII and the PvuI digests respectively were observed. 
These are the result of partial digestion. This construct was subsequently electroporated 
into M. smegmatis mc2 155. 
Figure 3.11. Restriction profiling of the cydDC knock out construct with various restriction endonucleases. (A) Map of the construct showing
the sites where restriction sites are located. (B) Restriction digest of the construct visualized on a 1% agarose gel. Labelled from left to right:
Lane1 and 2, Marker III and the uncut control. Lane 3-9, digest with the following restriction enzymes: BamHI, EcoRI, HindIII, mluI, PstI, PvuI
and PvuII respectively. HindIII and PvuI yielded two stray bands respectively which were not expected following digestion. (C) Table showing
enzymes used and the expected band sizes. The question marks indicate the products of partial digests.
A
5148 bp
1584 bp
925 bp
21226 bp
4268 bp
2027 bp
1375 bp
831 bp
564 bp
uncut
MIII PvuI PvuIIPstIMluIHindIIIEcoRIBamHI
3594
3072/3012
7035 6876
1863
766
739
9910
2007
??? 4298
780
1987
4417
1353
4058
5696
3125
5940
3296
819
916
2557
726
2229
2384
5311
???
B
Enzyme Expected band sizes (bp)
BamHI 3012, 3072, 7035
EcoRI 1863, 766, 3594, 6876
HindIII 27, 739, 9910, 2007, 436
PvuI 453, 480, 726, 2229, 2384, 
916, 477, 143, 5311
PvuII 144, 819, 363, 2557, 5940, 
3296, 
MluI 425, 780, 1987, 4417, 1353, 
99, 4058
PstI 5696, 4298, 3125
C
Fragment sizes are shown in bp
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3.10.1 Construction generation of the double deletion of the cydDC operon by 
recombineering in M. smegmatis 
As already mentioned, due to technical difficulties, two strategies to knock out the 
cydDC operon in M. smegmatis were adopted. The substrate to generate an inframe 
double deletion allele was designed as previously described (Methods and materials 
section 2.15). The substrate was successfully designed and ordered through 
GeneScript. The streptomycin cassette was subsequently cloned into the plasmid 
designated pUC 57:cydDCKO. The aadA marked construct was mapped with several 
restriction enzymes (Figure 3.11.1). 
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A double digest of BamHI and PvuI and PvuI respectively yielded partial digests while 
the SalI digest did not yield expected band sizes. The plasmid was sequenced to 
confirm SalI restriction sites. The PacI fragment of the substrate was successfully PCR 
amplified and electroporated into wildtype M. smegmatis. Several colonies emerged 
after four days of incubation at 37 °C. Due to time constraints, these were not screened 
to confirm cydDC deletion. 
Figure 3.11.1. Extraction and restriction profiling of streptomycin marked knock out construct of ΔcydDC
generated by lamda phage genetic recombineering. Separation of fragments was done on a 1% agarose
gel by electrophoresis. All fragments except the BamHI/PvuI double digest and SalI yielded expected band
sizes. The BamHI/PvuI double digest shows yielded partial digests. The plasmid was sequenced to verify
the SalI site.
BamHI 2033; 896; 328; 
1143; 429
EcoRV 3403; 1426
MluI 1376; 3453
NruI 4508; 321
NspI 2912; 1917
PacI 2111; 2718
PvuI 328; 1143; 2462; 
896
SalI 1597; 3232
Expected band sizes (bp)Enzyme
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3.12  Selection of Single Crossover recombinants 
A 100 mL culture of M. smegmatis mc2 155 was cultivated to log phase and washed 
three times with 10% glycerol as previously described (See 2.7.2). At least 1 µg of 
purified DNA (See 2.4.2) of the final construct was mixed with 400 µL of washed cells 
and electroporated as previously described (See 2.7.2). The following controls were 
included alongside the experimental: No plasmid control and 2 µL of 560 ng of 
pMV306H. Additionally, 10X serially diluted unwashed culture was also plated to assess 
the proportion of cells lost during the washing procedure. These troubleshooting 
approaches were used as various technical difficulties were encountered during 
electroporation. Eventually, several blue, single crossover recombinants emerged from 
various electroporations. These isolates were subjected to counterselection as 
described in the Materials and Methods (2.14)  
3.13. Genomic confirmation of the ΔcydDC mutant  
Following sucrose counter selection, ten white colonies were screened as outlined in 
2.6.1, five potential mutants (DCOs) were obtained by a preliminary PCR screen, as 
evidenced by the presence of  220 bp mutant amplicon (Figure 3.12).  
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Clones 41, 44, 47, 48, and 49, which displayed this band were then confirmed by 
southern blot analysis as mutants Figure 3.12. 
 
2176 bp
154 bp
1766bp
1230bp
1033bp
653bp
517bp394bp
298bp
234bp
MVI
340 bp
220 bp
41 42 43 44 45 46 47 48 49 50 SCO -vemc2 155
Figure 3.12. Preliminary screen for potential mutants [Double Cross Overs (DCOs)] by PCR. A) Schematic
illustration of primer binding sites (red arrows) for screening of DCOs. B) PCR amplicons were separated on a 1%
agarose gel by electrophoresis and visualized with GeneSnap software. Loaded from left to right, Marker VI in lane 1,
lane 2-11, sample 41-50 respectively. Lane 12-14, M. smegmatis mc2 155, Single Cross Over (SCO) and No template
control respectively. Five DCOs were obtained from the screen and were taken forward for confirmation by southern
blot analysis.
DCO mutant
Wild-type
M. smegmatis mc2 155 
chromosome
cydDcydC
SCO 2 cydDC
PacI cassetteΔcydDC
340 bp220 bp
DCO
ΔcydDC
220 bp
SCO 1
PacI cassette ΔcydDCcydDC
220 bp340 bp
A
B
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Figure 3.13. A 
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PstI
AatII
PstI
AatII PstI AatII
Wild type 
1954 bp
1430 bp
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3.13  Construction of the M smegmatis ΔcydDC genetically complemented 
strain.  
To complement the M. smegmatis ΔcydDC strain, the plasmid used for heterologous 
complementation in E. coli (section 3.4) was used. This plasmid was electroporated into 
the mutant strain and the resulting genetically complemented derivative 
(ΔcydDC::pMV_cydDC) was used for phenotypic analysis.  
Figure 3.13. Southern blot analysis for mutant confirmation. A) Clone manager maps giving expected band sizes
for the mutant (2688 bp for the AatII digest, and 4688 bp for the PstI digest), wild-type (1430 bps for the AatII
digest, and 1954 bps for the PstI digest). Also shown is the map of the down stream integration Single Cross
Over (DS_SCO) yielding 5590 bp and 1430 bp for the AatII digest, 4607 and 1954 bps for the PstI digest). The
green upstream region was used as a probe.
WT SCO 41 44 47 48 49
5590 bp
1430 bp
2688 bp  (mutant band)
B. AatII digest
SCO WT41 44 47 48 49
4607 bp
1954 bp
4688 bp (mutant band)
C. PstI digest
cydDC
US_R DS_RX X
M. smegmatis 
chromosome
1176 bp 864 bp
ΔcydDC
Marker
Electroporate
Southern blot analysis
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3.14.  Deletion of cydDC leads to loss of the heme d peak in the membrane 
fraction of M. smegmatis 
The role of the cydDC in CbdO biogenesis was assessed by absorption difference 
spectroscopy in M. smegmatis and its derivative strains. Cultures of M. smegmatis 
mc2 155, M. smegmatis ∆cydDC strain and the ΔcydDC::pMV_cydDC complement 
were cultivated in a bioreactor at 21% and 1% dissolved oxygen tension as detailed in 
(2.3). A gradual decline in dissolved oxygen was maintained at 1% for at least one hour. 
Cultures were lysed with a french press as detailed in (2.17) and the cell lysate 
prepared for extraction of membrane fractions as previously described (See 2.18). 
Absorption difference spectroscopy was performed on all three strains as outlined in 
(Materials and Methods section 2.20).  The results from these experiments are shown in 
(Figure 3.14).  
The reduced minus oxidized spectra for wild-type M. smegmatis mc2 155 showed a 
diagnostic peak of CbdO at 630 nm, while the same was absent in the cydDC mutant 
strain. Complementation with M. smegmatis cydDC operon restored the loss of CbdO 
proving that the cydDC contributes to the biogenesis of the holoform of CbdO. 
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3.16. Growth kinetic analysis of M. smegmatis and its derivative strains. 
It has been demonstrated that loss of CbdO resulted in defective growth of M. 
smegmatis at reduced oxygen tensions, consistent with the proposed role of CbdO for 
growth under hypoxic conditions in E. coli (Kana et al., 2001). To further assess this, M. 
smegmatis was grown in a bioreactor at 21% air saturation (reflecting normoxic 
conditions), followed by a reduction in the air saturation in the bioreactor to 0.7% air 
saturation. Under normoxic conditions, loss of CbdO did not affect growth (Figure 3.15). 
However, under hypoxic conditions, the growth rate of M. smegmatis was significantly 
lower than that of the wild type. The genetically complemented counterpart displayed 
growth kinetics comparable to wild-type (Figure 3.15). Due to time constraints, this 
experiment was done only once before submission of the MSc dissertation.  
Figure 3.14. Absorption difference spectroscopy of M. smegmatis mc2 155 and its derivative strains. A) M.
smegmatis mc2 155 B) M. smegmatis ΔcydDC and C) ΔcydDC::pMV_cydDC. Deletion of the M. smegmatis
cydDC resulted in the loss of cytochrome bd oxidase (CbdO). This is exemplified by the absence of the
heme d signature peak which is a diagnostic feature of CbdO. Complementation with the M. smegmatis
cydDC restores this signature peak. This is also exemplified by the increase in expression of certain
cytochromes which were dramatically reduced upon deleting the cydDC.
A
B
C
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3.17 The ΔcydDC mutant strain is sensitive to exogenous hydrogen peroxide 
It has been previously established in E. coli that the presence of CbdO protects from 
oxidative stress. To prove that the same holds in mycobacteria, cultures of M. 
smegmatis and its derivative strains were washed twice in 7H9 as previously described 
(See 2.7.1) and treated with 2 mM (H2O2) for 15 and 30 min to induce oxidative stress 
as detailed in 2.19.2 (Figure 3.16).  
Figure 3.15. Growth curve analysis of M. smegmatis and its derivative strains in 7H9 in a Bioflow 110
fermentor at 21% and 0.7% dissolved oxygen (dO2 ). Blue squares represent M. smegmatis mc
2 155,
Red squares represent M. smegmatis deficient of the cydDC encoded ABC-type transporter (ΔcydDC)
and green triangle, M. smegmatis ΔcydDC complemented with M. smegmatis cydDC operon in its
native locus. C) ΔcydDC::cydDC. M. smegmatis deficient of the cydDC operon struggles to grow at low
oxygen tension. Bacteria were first grown at 21% air saturation and after 10 hours at 0.7% air
saturation. This data set represents one experimental replicate of each strain as alreadydescribed.
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As expected, ΔcydDC mutant strain was more sensitive to H2O2 treatment relative to 
wild-type cells, which showed tolerance after 15 min exposure. This phenotype was 
rescued when the mutant gene was complemented with the wild-type gene (Figure 
3.16). 
3.18. The ΔcydDC mutant strain fails to exit stationary growth phase 
It was previously observed that the E. coli strain lacking the cydD gene had a stationary 
phase growth phenotype were it could not re-establish growth when plated on solid 
media with minimal glucose. This assay was used during heterologous 
complementation. Hence, the ability of M. smegmatis cydDC mutant strain to exit from 
stationary growth phase was investigated. M. smegmatis and its derivative strains were 
-2.00E+09
0.00E+00
2.00E+09
4.00E+09
6.00E+09
8.00E+09
1.00E+10
1.20E+10
1.40E+10
Log CFU/mL
M. smegmatis strains
T15 min
T30 min
Figure 3.16. Survival of M. smegmatis and its derivative strains to exogenous hydrogen
peroxide (H2O2). M. smegmatis and its derivatives were exposed to 2% exogenous H2O2 at
different time points (15 and 30 min). Each graph represents a mean value of three
independent experiments for each strain. A 10-fold dilution series of each culture was plated
and the colony forming units (CFU/mL) were enumerated. Shown are the colonies that
emerged on the 107, 108 and 109 dilutions. Notably, ΔcydDC was sensitive to exposure to
exogenous H2O2. Complementation with the M. smegmatis cydDC operon rescued
sensitivity to H2O2. This data set represents a standard deviation of three experimental
replicates. Data analysis with the student t test showed statistical difference with a p value of
0.035 between wildtype M. smegmatis and ΔcydDC mutant strain.
P=0.126
P= 0.035
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cultivated in Sautons minimal media for mycobacterial growth and plated on 7H10 
containing 0.05% glucose. As expected the mutant was not able to exit out of stationary 
phase while the wild type and genetically complemented strain was able to exit 
stationary phase (Figure 3.17).  
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Figure 3.17. Nutrient starvation assay in M. smegmatis and its
derivative strains. The cultures were cultivated in minimal media for
mycobacterial growth and starved for 7 days. Serial dilutions of each
strain were plated and the ability to resume growth in 7H10 with
minimal glucose media at 37  C was assessed.
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4.  Discussion 
With a plethora of antibiotic armament and numerous other control measures to combat 
TB, the disease remains a public health concern, deeply embedded in low income 
societies. This is in part due to the inherent ability of Mtb to rapidly develop resistance to 
many of the anti-TB agents or assume a dormant state during immune assault and drug 
exposure, only to reactivate later and cause clinical disease. This bacterial scourge has 
necessitated a search for the identification of new drug targets which can be exploited in 
the design of new drugs with novelty in their action. For this, the ETC of Mtb is relatively 
unexplored and the validation of Bedaquiline highlights the ETC‘s potential to be mined 
for new drug targets. In this regard, CbdO is present in a number of pathogenic 
microbial species including Mtb. In this study, we endeavored to understand the role of 
the cydDC operon in the assembly of CbdO and their role in M. smegmatis. We believe 
this understanding will contribute to ending the TB epidemic. 
4.1 Modeling the CydDC subunits 
According to the Smegmalist database, the genome organization of the cyd gene 
cluster in M. smegmatis suggests that cydD and cydC are transcribed as a single 
polycistronic mRNA message (Figure 3.1 and Figure 4) (Aung et al., 2014). Also, the 
role of the cydDC operon is unknown according to the Smegmalist database (Figure 4).  
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However, the Tuberculist database annotates the cydDC homologs in TB as 
heterodimeric subunits of the ABC-type transporter superfamily with a possible role in 
intermediary metabolism and respiration (Figure 4). To elucidate this, structural analysis 
of the CydDC subunits was successfully completed (Figure 3.3). These analyses 
confirmed that the M. smegmatis cydDC genes encode heterodimeric subunits of the 
ABC-type transporter superfamily (Poole et al., 1993). Each subunit is characterized by 
the presence of two domains, a single TMD which preserve substrate binding sites and 
a single ABC domain which is a four membered helical domain with conserved residues 
(Linton and Higgins, 1998, Cruz-Ramos et al., 2004, Poole et al., 1993). In addition to 
these domains, the topology of each subunit shows three minor periplasmic loops and 
two major cytoplasmic loops (Figure 3.3). All of these features, together with the four 
membered helical domain are characteristic of the ABC-type superfamily of 
transporters. These conserved residues and domains are found in CydDC homologues 
Figure 4. Diagrammatic illustration of the cyd gene cluster organization in (A) M. smegmatis and (B) Mtb respectively. In both
organisms, the cydDC are operonic, The function of the cydDC operon is unknown in M. smegmatis while their counterpart in Mtb are
predicted to function in metabolism and respiration.
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across the three domains of life, and have helped to define ABC-type transporters 
(Linton and Higgins, 1998, Higgins, 2001). The M. smegmatis CydDC subunits are no 
exception in this regard. Both subunit III and IV preserve a total of 5 conserved residues 
in the ABC domain (Figure 3.3). The following conserved residues were identified for 
subunit III and subunit IV respectively, the highly conserved Walker A motif at position 
330 and 338 bp. This motif is characterized by the GxxGxGKS/T motif, where bold 
capital letters signify conserved residues and x represents any amino acid. This motif is 
conserved across many bacterial species (Davidson et al., 2008). The Q loop defined 
by a conserved glutamine (xxQxx) was identified 14 and 34 amino acids downstream of 
the Walker A motif at position 344 and 364 bps respectively. This residue is not 
conserved across all microorganisms but has been identified in most proteobacterial 
species (Linton and Higgins, 1998, Higgins, 2001, Davidson et al., 2008). The signature 
motif represented by the LSLGQ motif was mapped to position 429 bp and is present in 
most microorganisms as LSGGQ motif, however, in several mycobacterial species, this 
motif was identified as the LSLGQ motif (Figure 3.3). The Walker B motif was mapped 
to position 449 bp and is characterized by xxxxDEPT were bold capital letters represent 
conserved residues whilst x is any hydrophobic residue (Davidson et al., 2008). Finally, 
the H-loop defined by a conserved Histidine xxHxx was mapped to position 496 bp, 
were x is any amino acid. Notably, the organization of the conserved residues in the 
helical ABC domain and the structural topology for the CydDC in M. smegmatis is 
consistent in E. coli (Cruz-Ramos et al., 2004). Although X-ray crystallographic 
structures of the CydDC subunits have not been determined, structural prediction 
algorithms such as ITTASER have enabled preliminary assessment of these subunits 
with high structural threading and prediction confidence. The M. smegmatis CydDC 
subunits have high sequence similarity and structural identity to some of the best 
characterized CydDC subunits (Cruz-Ramos et al., 2004). Collectively, from the above 
analysis, we conclude that the mycobacterial cydDC genes also encode heterodimeric 
members of the ABC-type transporters. Moreover, given the high degree of 
conservation between the M. smegmatis and the E. coli homologue, we predicted that 
the mycobacterial counterparts most likely transport that same metabolites as those 
transported by the E. coli CydDC transporter (Pittman et al., 2002, Pittman et al., 2005).  
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4.2 The presence of the cydDC genes is necessary for CbdO biogenesis 
The high degree of conservation between the E. coli and mycobacterial CydDC 
transporters suggested that these transporters would be functionally interchangeable. 
To further test this, we sought to heterologously express the mycobacterial CydDC 
transporter in an E. coli mutant that lacked cydD (Poole et al., 1989). In E. coli, loss of 
cydD leads to defective CbdO assembly. Absorption difference spectroscopy of the E. 
coli cydD mutant and its heterologous derivative strains revealed interesting outcomes. 
First, reduced minus oxidized cytoplasmic fractions of wild-type E. coli revealed 
absorption peaks associated with both types of oxidases (cytochrome bo oxidase and 
CbdO) that are induced under various oxygen tensions (Figure 3.6). CbdO biosynthesis 
was evidenced by the 630 nm chlorin heme d peak, which has been reported by various 
studies as the diagnostic peak denoting the presence of CbdO (Poole et al., 1989, 
Georgiou et al., 1987). Other spectral features associated with CbdO biogenesis 
observed include hemoprotein b558 and b595 (Poole et al., 1983) (Figure 3.6). Notably, as 
the E. coli strains were grown under reduced oxygen tension, where the CbdO is 
optimally induced, a greater abundance of the above-mentioned peaks, related to 
CbdO, were observed relative to the reduced levels of the diagnostic 600 nm peak 
associated aa3 type CcO. The E. coli derivative lacking cydD displayed full spectral 
features of CcO which is the main terminal electron acceptor under high oxygen 
tension. However, some of the spectral features associated with CbdO were missing, 
indicating the presence of defective CbdO (Figure 3.6). For instance, the signature 
diagnostic chlorin heme d peak was not present (Figure 3.6) consistent with 
observations of Poole and coworkers (Poole et al., 1989).  
Heterologous expression of the putative Mtb exporter restored the loss of CbdO as the 
chlorin heme d signature reappeared in the ∆cydD (pSE::pGcyd) strain that ectopically 
expressed the Mtb cydDC genes, Figure 3.6. Other peaks such as hemoprotein b558 
and b595 associated with CbdO biogenesis were also detected near their absorption 
maximum. These data provide the first evidence that heterologous expression of the 
putative Mtb transporter is able to restore loss of CbdO biogenesis due to cydD deletion 
in E. coli suggesting conservation of function in mycobacteria.  
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To further investigate the biological role of the cydDC-encoded ABC-type transporter in 
mycobacteria, these genes were deleted in M. smegmatis and resulting mutant was 
tested for CbdO biogenesis using membrane spectroscopy.  . As observed in E. coli, the 
ΔcydDC knock out strain of M. smegmatis was unable to synthesize a holoform of 
CbdO characterized by the presence of the 630 nm peak in the reduced form (Figure 
3.14). This is consistent with observations made by several studies in different gram 
negative and gram positive organisms (Poole et al., 1989, Georgiou et al., 1987, 
Winstedt et al., 1998, Kelly et al., 1990). Furthermore, genetic complementation with M. 
smegmatis cydDC genes restored CbdO assembly and certain cytochromes whose 
expression was decreased or completely abrogated due to cydDC loss (Figure 3.14). 
For instance all cytochromes detected near the 520 nm region were missing and these 
were restored by genetic reconstitution of the cydDC allele. As with the E. coli strains, 
membrane spectroscopy was conducted under microaerophillia and the expression of 
the diagnostic 600 nm peak associated with CcO was significantly reduced relative to 
CbdO as exemplified by difference in peak sizes. This is due to the differential 
expression of each oxidase as dictated by O2 saturation as has been demonstrated in 
M. smegmatis (Kana et al., 2001, Matsoso et al., 2005). Collectively, these data show 
that the CydDC encoded ABC-type transporter is essential for CbdO biosynthesis in M. 
smegmatis. To further assess the functionality of the cydDC genes in E. coli and to 
assess the phenotypes of the M. smegmatis ΔcydDC knockout, various assays that 
provide insight into CbdO function were conducted. 
4.3  Growth kinetics of E. coli derivative strains and the M. smegmatis ΔcydDC 
mutant 
It is widely accepted that CbdO is induced under conditions of low oxygen tension but 
this enzyme has also been implicated in stationary phase growth and survival (Siegele 
and Kolter, 1993) . To test stationary phase survival, a protocol adapted from Cruz-
Ramoz and co-workers was adopted (Siegele and Kolter, 1993). E. coli and its 
derivatives were cultivated in a final volume of 150 mL of LB media in 250 mL flasks 
and incubated at 37 °C with shaking at 50 rpm. Initially, all strains displayed comparable 
growth rates. At the onset of exponential growth phase, all strains exhibited identical 
` 
105 
 
growth patterns (Figure 3.7). This is most likely due to the induction of the main aerobic 
branch (CcO). At OD600 1.4, the growth pattern of E. coli ∆cydD began to decrease as 
exemplified by a decrease in growth rate (Figure 3.7). The cydD null mutant appeared 
to be growing exponentially but with a decrease in biomass, a feature that was noted till 
the end of the growth curve, when the bacteria entered stationary phase. As the 
difference was marginal, the biological significant of this is unclear but it points towards 
a growth defect experienced by ∆cydD due to the absence of a functional CbdO at the 
onset of stationary phase.  
A previous study reported the induction of CbdO at late exponential and stationary 
growth phase, under aerobic conditions (Anraku and Gennis, 1987). This implicates 
CbdO in facilitating growth and providing for energetic requirements beyond the 
exponential growth phase. This was confirmed in this study by heterologous expression. 
The ability of E. coli cydD null strain to increase in biomass at stationary phase when 
complemented with the Mtb cyd operon provided evidence that, heterologous 
expression of the Mtb pGcyd operon is able to correct the growth defect associated with 
∆cydD at the onset of stationary phase and further shows that a functional terminal 
oxidase in a form of CbdO is necessary for optimum growth at stationary phase. 
Similarly, growth kinetics of M. smegmatis and its derivative strains was performed to 
investigate the effect of the loss of the cydDC operon. This was done in a meticulously 
controlled environment where oxygen supply was tightly monitored in a bioreactor 
(Kana et al., 2001). As with the E. coli growth kinetics, M. smegmatis and its derivative 
strains displayed comparable growth kinetics until OD readings of approximately 1.2. 
Until this point, M. smegmatis cells were grown at an air saturation of 21% dO2. This 
was maintained for approximately 45 min before dropping to air saturation of 0.7% to 
induce CbdO activity (Aung et al., 2014). At this point the growth trend of the graphs 
changed where the growth rate of ΔcydDC mutant was dramatically lower when 
compared to the wild-type and genetically complemented strain. This is consistent with 
the observation made by Kana and coworkers with the competitive growth of M 
smegmatis and its cydAB mutant derivative at 5 % and 0.5% dissolved O2 (Kana et al., 
2001). The wild-type and the ΔcydDC::pMVpcydDC complement continued to grow at 
comparable rates until stationary phase while the ΔcydDC knock out strain struggled to 
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grow at stationary phase under hypoxic conditions (Figure 3.15). Many factors can 
affect the growth rate of M. smegmatis. These data implicated defective CbdO function 
under hypoxic conditions due loss of the cydDC operon and further confirmed that in 
mycobacteria, the cydDC genes are necessary for CbdO function. 
4.4  The role of CbdO in exit from stationary phase. 
Microorganisms respond to nutritional deprivation by activating starvation or stationary 
growth phase programs that allow for shut down of growth in an orderly manner and 
survival under prolonged starvation. Also, changes in gene expression partially account 
for the differences in physiology and morphological traits of stationary cells. Transposon 
mutagenesis was used to identify genes that failed to resume growth after several days 
of starvation (Siegele and Kolter, 1992). The phenotype was designated a Sur-
phenotype due to an incurred survival defect. The mutation was later mapped to the 
cydC locus (Siegele and Kolter, 1993, Siegele and Kolter, 1992). However, later cydD 
was also described by another study as having a stationary phase survival defect 
(Goldman et al., 1996a). To investigate the functionality of the mycobacterial cydDC in a 
similar biological context, the heterologously complemented E. coli strains were tested 
for exit from stationary phase. Unexpectedly, the E. coli cydD mutant was able to form 
colonies in minimal media after 7 days of starvation. Considering that the first group to 
describe this phenotype conducted their study by transposon mutagenesis, these 
discrepant results could be due to aberrant transposon insert in other parts of the 
genome. Nonetheless, a stationary phase exit defect phenotype was discernible. There 
are regulatory mechanisms in place that control coordinated re-entry of nutritionally 
starved cells back in cell growth cycle. For instance, bacteria are able to metabolize 
fresh nutrients but do not immediately reinitiate grow (Oliver et al., 1991, Roszak and 
Colwell, 1987). This suggests that bacteria can respond to an increase in nutrients but 
remain paralyzed for growth or alternatively are able to re-initiate growth at a later time 
point. Other dogma hold that specific proteins are synthesized during out growth from 
stationary phase but are not necessary for maintenance of growth (Ross et al., 1990). 
For instance, Ross and co-workers established that when E. coli is sub-cultured in fresh 
media, induction of the fis genes occurs, but the expression of the same is diminished 
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once growth is re-established (Ross et al., 1990). However, in this regard, lack of 
extensive re-growth from stationary growth phase was simply attributed directly to the 
loss of CbdO (Siegele et al., 1996). When there is defective CbdO, under 
microaerophillic conditions, there is no terminal electron acceptor, alluding to stalled 
aerobic respiration or the need to direct electron flux through another branch of the 
ETC. Heterologous expression with putative mycobacterial exporters were able to 
restore the stationary phase defect, possibly signaling the presence of a functional 
terminal oxidase. It is unclear why heterologous complementation with the Mtb cydDC 
genes did not recue the phenotype of the E. coli cydD mutant but we expect that this 
may be related to the promoter or expression system used. For the M. smegmatis 
genes, the single pMV306 vector was used, with the native cydDC promoter region. For 
the Mtb genes, the pSE100 vector was used, which contained the tetracycline operator 
upstream of the native cydDC promoter, followed by the cydDC genes. These 
differences, and other unknown reasons, could have contributed to the inability of the 
Mtb genes to complement the E. coli cydD mutant defects. In M. smegmatis, loss of the 
cydDC genes also led to defective exit from stationary phase confirming that in 
mycobacteria also, the CbdO is required for the successful transitions between 
replicative and non-replicative states.  
4.5  Heterologous expression corrects temperature sensitivity phenotype 
One of the highly conserved responses to environmental stress is the heat shock 
response (Yura and Nakahigashi, 1999). E. coli has approximately 20 genes which 
constitute an operon under the coordinate control of sigma factors which appear to be 
auto regulated (Yura and Nakahigashi, 1999, Goff and Goldberg, 1985). Furthermore, 
the expression of this operon seems to increase following an increase in growth 
temperature. Survival under adverse environmental conditions is a reality with which all 
microorganisms must cope. Fluctuations in temperatures which permit growth is one 
such condition (Siegele and Kolter, 1993). E. coli has an optimal growth temperature of 
37 °C. However, E. coli lacking cydD was reported to have a temperature sensitive 
growth defect at both 37 and 42 °C (Siegele and Kolter, 1992, Siegele and Kolter, 
1993). This defect was originally described when cydD was isolated by transposon 
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mutagenesis in a screen for genes that allowed growth of E. coli at high temperatures 
(Delaney et al., 1992). The gene was initially designated HtrD denoting a high 
temperature requirement. Further mapping and characterization of the gene showed 
that HtrD mapped to the same genomic locus as cydD, which had previously been 
described (Poole et al., 1989). The nucleotide sequence of HtrD was the same as cydD 
however had an extra Guanine at position 394 bp. Therefore, heterologous expression 
of the putative mycobacterial exporters yielded interesting findings. We tested the ability 
of E. coli ∆cydD for growth at high temperatures. Across all three experimental 
replicates, a few colonies were observed for E. coli cydD (Figure 3.8). Heterologous 
expression of the M. smegmatis cydDC genes corrected the temperature sensitive 
phenotype. The E. coli cydD mutant displayed far less platable CFUs with reduced 
colony morphology following 24 hrs incubation period, this phenotype was completely 
corrected when the M. smegmatis cydDC was used for heterologous complementation. 
However, it must be noted that the original study reported late emerging colonies and 
these were attributed to a high reversion rate (Delaney et al., 1992). These, pin point 
colonies were observed in this study also (data not shown). It was interesting to observe 
that the Mtb pGcyd operon restored the loss of CbdO spectroscopically, but only 
partially restored the temperature sensitivity phenotype. A possible explanation for this 
has been detailed above. 
4.6 Loss of CbdO leads to sensitivity to oxidative stress induced by hydrogen 
peroxide 
One of the earlier findings in bacterial respiration was that E. coli mutants defective in 
the CbdO due to cydD or cydC loss were sensitive to exogenous H2O2 (Poole et al., 
1989). Sensitivity to H2O2 is historically been attributed to DNA damage (Imlay and Linn 
1986). In E. coli, the damage that occurs as a result H2O2 activity yields modes of killing 
that are distinguishable based on metabolic, genetic and kinetic criteria. Metabolically 
inactive cells exhibit a single mode of killing whereas metabolically active cells exhibit a 
mode of killing characterized by rapid killing kinetics when low amounts of peroxide are 
employed momentarily (1-3 mM) (Imlay and Linn 1986). In this study, the E.coli cydD 
mutant was clearly susceptible to treatment with 2 mM exposure to H2O2. H2O2 
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displayed rapid killing kinetics at 15 min and this effect was abrogated by heterologous 
expression of putative mycobacterial exporters. The killing effect retained potency at 
extended exposure time points. No CFUs were recorded for the E. coli cydD mutant at 
30 min of exposure to H2O2 (Figure 3.9). Heterologous expression was able to correct 
sensitivity to H2O2 (Figure.3.9). 
Similarly, M. smegmatis and its derivative strains were assayed for ability to survive 
exogenous exposure to H2O2. As expected, the ΔcydDC mutant strain displayed 
hypersensitivity to 2 mM of H2O2, (Figure 3.16). This phenotype was more severe for the 
M. smegmatis ΔcydDC knock out strain at extended incubation periods). CbdO has 
been reported to possess both superoxide activity in A. vinelandii and peroxide activity 
in M. smegmatis (Kelly et al., 1990, Lu et al., 2015). The absence of CbdO renders 
these bacteria hyper-susceptible to both oxygen radicals and nitrogen reactive 
intermediates. From this, we conclude that the presence of the cydDC operon in M. 
smegmatis contributes to a functional terminal CbdO, which under oxidative stress 
detoxifies reactive oxygen intermediates that can cause cell death. 
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5.  Conclusion 
The mycobacterial ETC has become a prominent area for the discovery and validation 
of new drug targets for TB. In this regard, the CbdO has been of particular interest and 
whilst the role of the structural subunits of this enzyme have been extensively studied, 
the assembly of this respiratory complex in mycobacteria has remained a mystery. In 
this study, we advance the scientific knowledge on the mycobacterial CydDC by 
demonstrating that this transporter is functionally interchangeable with its counterpart 
from E. coli. Consequently, we expect that the mycobacterial cydDC-encoded ABC-type 
transporter retains similar biological roles as that in E. coli, the principal one being the 
assembly of a functional CbdO. We confirmed this hypothesis by generating a mutant of 
M. smegmatis that lacked the cydDC genes and demonstrated that it cannot assemble 
CbdO and thus displayed reduced growth under hypoxic conditions and increased 
sensitivity to oxidative stress. This work provides novel insight into the mycobacterial 
ETC and creates various new avenues for future studies to validate the CbdO as a 
novel TB drug target.   
 
6. Limitations and future studies 
This study presented herein has various limitations. Some technical limitations include 
the inability of the Mtb cydDC genes to complement some of the E. coli cydD mutant 
defects. This could be addressed by using a different vector system and monitoring the 
expression of heterologous genes. Also, the growth kinetics experiments for M. 
smegmatis under hypoxic conditions could require biological repeats, which could not 
be completed due to time limitations. This is currently being addressed as these are 
time consuming experiments because only one strain can be cultured in the bioreactor 
at any single time. Future experiments include the measurement of glutathione and 
homocysteine transport in the M. smegmatis ΔcydDC mutuant. In E. coli, these two 
metabolites have been proposed to be the substrates of the cydDC-encoded ABC-type 
transporter and hence, this requires validation in mycobacteria. Future experiments will 
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also include a study of the regulation of the cydDC operon under aerobic and hypoxic 
conditions.  
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7. Appendices 
Table A1: Bacterial culture Media ingredients recipes  
Medium  Components  
7H9  4.9 g powder, Middlebrook, 0.085 % NaCl, 0.2% glucose, 
0.2% glycerol, 0.05% Tween 80 (Autoclaved) 
 
7H10  19 g powder, 0.085 % NaCl, 0.2% glucose, 0.2% glycerol 
made up to 1 L in dH2O (autoclaved) 
 
2xTY  2% tryptone, 0.5% NaCl, 1% yeast extract dissolved in 
dH2O (autoclaved) 
 
LA  1% tryptone, 0.5% NaCl, 0.5% yeast extract dissolved in 
dH2O (autoclaved) 
 
LB  1% tryptone, 0.5% NaCl, 0.5% yeast extract, 1.5% agar 
dissolved in dH2O (autoclaved) 
 
M63  [10 g (NH4)2SO4, 68g KH2PO4, pH 7 with KOH = 5X stock] 
Working solution: 200 mL 5X stock,  
 
 
Table A2 Stock recipes for media supplementation 
Supplement  Components  
Glucose salts (100X)  20 g glucose, 8.5 g NaCl dissolved in 100 ml dH2O 
(autoclaved) 
 
Tween80 (25 %)  12.5 ml Tween80 dissolved in 40 mldH2O (filter sterilized)  
X-gal (2%)  1 g X-gal in 50 ml deionised DMF  
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Table A3 Solutions used in extraction of M. smegmatis genomic DNA 
Solution  Ingredients  
CTAB/NaCl  4.1 % NaCl, 10% N-cetyl-N,N, N-trimethyl ammonium 
bromidedissolved in dH2O (filter sterilized) 
 
TE buffer  10 mM Tris-HCl (pH 8), 10 mM EDTA dissolved in dH2O 
(autoclaved) 
 
 
Table A4 Solutions used for DNA precipitation 
Solution  Ingredients  
Chloroform: Isoamyl alcohol  24 ml chloroform, 1 ml isoamyl alcohol  
Sodium acetate  3M sodium acetate dissolved in dH2O, pH 5.2 
(autoclaved) 
 
Table A5 Solutions for extracting plasmids from E. coli 
Solution  Ingredients  
Solution I  50mM Glucose, 25mM Tris-HCl (pH 8), 10 mM EDTA 
dissolved in dH2O (autoclaved) 
 
Solution II  1% SDS, 0.2 M NaOH dissolved in sdH2O  
Solution III  3 M Potassium acetate, 11.5% Acetic acid dissolved in 
sdH2O 
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Table A6. Solutions for preparing competent E. coli cells 
Solution  Ingredients  
TfbI  30 mM Potassium acetate, 100 mM Rubidium chloride, 10 
mM Calcium chloride, 50 mM Manganese chloride, 15% 
v/v Glycerol made up in dH2O and pH 5.8 with dilute acetic 
acid 
 
TfbII  10 mM MOPS, 75 mM calcium chloride, 10 mM rubidium 
chloride, 15 % v/v glycerol made up in dH2O and pH 6.5 
with dilute NaOH 
 
 
Table A7. Electrophoresis solutions 
Solution  Ingredients  
TAE  (50x stock solution): 242 g Tris base, 57.1 ml glacial acetic 
acid, 100 ml   0.5 M EDTA (pH 8) make up to 1L in dH2O 
(1x working solution contains 40 mM Tris-acetate and 1 
mM EDTA) 
 
Ethidium bromide  10 mg/ml in sdH2O  
 
TableA8. Agarose gel recipe 
Gel percentage  Amount of Agarose in 50 mL TAE (g)  
0.8  0.4  
1  0.5  
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2  1  
 
 
Table A9. Southern blot solutions 
Solution  Ingredients  
Denaturation solution  0.5 M NaOH, 1.5 M NaCl in dH2O  
Depurination solution  0.25M HCl in dH2O  
TBE (5X)  Tris-Borate-EDTA powder (Sigma) dissolved in 2 L 
dH2O 
 
SSC (20X)  3M NaCl, 0.3M sodium citrate in dH2O  
Solution I  2X SSC, 0.1% SDS in dH2O  
Solution II  0.5X SSC, 0.1% SDS in dH2O  
Maleic acid buffer  1M Maleic acid, 1.5M NaCl in dH2O (adjust to pH 7.5 
with NaOH pellets) 
 
Wash buffer  0.1M Maleic acid buffer, 0.3 % Tween20  
Blocking solution (Roche)  1X blocking solution in maleic acid buffer  
Detection buffer  0.1M Tris-HCl, 0.1M NaCl in dH2O (pH 9.5)  
Antibody solution(Roche)  Dilute 1 in 10 000 in blocking solution  
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CSPD (Roche)  Disodium 2-chloro-5-(4-methoxyspiro (2-dioxetane-3,2 
(2-dioxetane3,2‟ -(5‟ -chloro)-tricyclo[3.3.1.1. 3, 7. 
]decan(-. 4-yl)-1-phenyl phosphate 
 
 
 
 
Appendix A10 
 
 
3 way stuff
M iii Uncut BamHi BspHi pvui BamHi/
Psti
1365
3388
4753
2384
2384
4102
651
Figure A10.2. Extraction and mapping of p2NIL.
BspHI 3388; 1365
BamHI 4753
PvuI 3853; 896
BamHI/ PstI 4102; 651
3 way fragment gel 
extraction
4753 bp
1143 bp
843 bp
M iii p2NIL USR DSR Uncut
Figure A10.3 Gel purification of three way fragments.
US 
Pvui
DS 
Mlui
992
755
109
143
Figure A10.1. Confirmation of specific 
amplification of genomic fragments
80VI 6560 -ve70 75
1176
Upstream 
PCR
VI 60 75 807065 -ve
864
Cycling conditions
• 95 0C-3 min
• 95 0C-30 sec
• Primer annealing-Gradient
• Primer extention-72 0C 1 min
• Final extention-72 0C 10min
• Hold-12 0C ∞
Downstream 
PCR
Figure A10.1. Gradient PCR of the Upstream and and downstream Region of 
cydD (1176 bp) and cydC (864 bp) respectively.
Figure A10. Intermediary steps in cloning showing Amplification of fragments, verification of amplicons and cloning
vector by restriction digest and gel purification of fragments
` 
117 
 
 
 
 
 
 
 
 
 
 
Enzyme Expected size
Hind III 2007, 4753
BamH I/Pst I 4102, 2658
Pvu II/EcoR I 5577, 1183
Mlu I 4776, 1353, 99, 532
Pvu I 2263, 2384, 1493, 477, 
143
Pvu II 6760
Sal I 6056, 670, 34
1375bp
21226 bp
5148 bp
3530 bp
2027 bp
1584bp
925 bp
831 bp
564bp
Figure 10. Restriction analysis of  clone 2 with various restriction enzymes
Figure A10.1. Restriction profile of suicide construct with various restriction enzymes.
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Appendix B Molecular weight markers 
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